Stock Code: 4123

CENTER LABORATORIES, INC.

2026 Annual Shareholders' Meeting

Meeting Handbook

(Translation)

June 12, 2026

(This English version handbook is the translation of the Chinese version and is for reference purposes only. If there is any discrepancy between the English version and Chinese version, the Chinese version shall prevail.)

TABLE OF CONTENTS

Chapter 1. Meeting Procedure

I. Call Meeting to Order

II. Chairperson's Address

III. Report Items

IV. Ratification Items

V. Discussion Items

VI. Extemporary Motions

VII. Meeting Adjourned

Chapter 2. Meeting Agenda

Time: 9:00 a.m., June 12, 2026 (Friday)

Venue: Room 447, 4F, Building E, No. 19-11, Sanchong Road, Nangang District, Taipei City (Nangang Software Incubator)

Meeting Format: Physical Shareholders' Meeting

I. Call Meeting to Order

II. Chairperson's Address

III. Report Items

Proposal 1

Subject: 2025 Business Report.

Explanation: The 2025 Business Report (please refer to pages 11 to 18 of this handbook).

Proposal 2

Subject: 2025 Audit Committee Review Report

Explanation: The 2025 Audit Committee Review Report (please refer to page 19 of this handbook).

Proposal 3

Subject: 2025 The Distribution of Employees' Compensation and Directors' Remuneration Report .

Explanation:

1. The Company's profit for 2025 (referring to profit before tax prior to the distribution of employees' compensation and directors' remuneration) amounted to NT$11,577,211,959. In accordance with the Articles of Incorporation, 0.15% was appropriated as employees' compensation, amounting to NT$17,365,818 (of which 60%, i.e., NT$10,419,491, was allocated to non-managerial employees), and 0.15% was appropriated as directors' remuneration, amounting to NT$17,365,818, all of which were distributed in cash.
2. Any difference between the above remuneration and the estimated amounts recognized in the financial statements shall be accounted for as a change in accounting estimate and recognized in profit or loss for 2026.

Proposal 4

Subject: 2025 Directors' Remuneration Report.

Explanation:

1. The Company's policies, systems, standards, and structure for the remuneration of directors (including independent directors) are described as follows, together with the relationship between remuneration and factors such as duties, risks, and time commitment:
   (1) Pursuant to Article 25 of the Company's Articles of Incorporation, where the Company records profits in a given year, directors' compensation shall not exceed 2% of such profits. In addition, all directors receive attendance fees for participation in Board meetings, and independent directors receive attendance fees for participation in meetings of functional committees.
   (2) Independent directors receive fixed monthly remuneration and are also eligible to participate in the annual distribution of directors' compensation.
   (3) The allocation of directors' remuneration of the Company is reviewed by the Remuneration Committee based on the results of the Board performance evaluation (evaluation criteria include the level of participation in the Company's operations, enhancement of the quality of Board decision-making, Board composition and structure, the nomination and continuing education of directors, and internal control) and the results of directors' self-evaluations (assessment criteria include understanding of the Company's objectives and missions, awareness of directors' responsibilities, participation in the Company's operations, internal relationship management and communication, professional competence and continuing education, and internal control). In addition, the Remuneration Committee takes into consideration prevailing industry practices, the Company's operating conditions, risk management, and factors such as the responsibilities assumed, contributions, and performance of directors. After assessing the reasonableness of directors' remuneration, the proposal is submitted to the Board of Directors for deliberation and approval. Due to a significant increase in after-tax net income in fiscal year 114, the directors' remuneration allocated in accordance with the Articles of Incorporation has increased. The total amount of directors' remuneration is NT$17,365,818. Based on the results of performance evaluations, except for Chairperson Wang Su-chi, the representative of Jiaxuan Technology, who receives a higher allocation due to greater involvement in operations and contributions, the remaining directors are allocated remuneration on a pro rata basis according to their actual tenure.

2. Details of directors' remuneration for 2025 are provided on page 20 to 21 of this handbook.

Proposal 5

Subject: 2025 Material Related Party Transactions Report.

Explanation: The Company had no material related party transactions in 2025.

Proposal 6

Subject: Report on the Status of Private Placement.

Explanation: The Company obtained approval at the shareholders' general meeting on June 26, 2025 to conduct a private placement of common shares for cash capital increase, with a total amount not exceeding 30,000,000 shares, to be carried out in two tranches within one year from the date of the shareholders' resolution. As the implementation period was nearing expiration and no qualified specific persons had been identified, the Board of Directors resolved on April 14, 2026 not to proceed with the private placement within the remaining period.

Proposal 7

Subject: Report on the Status of Issuance of the 8th Domestic Unsecured Convertible Corporate Bonds and the 9th Domestic Unsecured Convertible Corporate Bonds.

Explanation: The status of issuance of the Company's 8th domestic unsecured convertible corporate bonds and 9th domestic unsecured convertible corporate bonds is provided (please refer to page 22 of this handbook).

IV. Ratification Items

Proposal 1

Subject: Ratification of the Company's 2025 Business Report and Financial Statements. (Proposed by the Board of Directors)

Explanation: The Company's standalone financial statements and consolidated financial statements for 2025 have been audited by CPAs Cheng, Chung-Hao and Chi, Chia-Yu of Full-Fill & Co., CPAs, and, together with the Business Report, have been reviewed by the Audit Committee and found to be in order. Approval is hereby respectfully requested. (Please refer to pages 11 to 18 and pages 23 to 45 of this handbook.)

Resolution:

Proposal 2

Subject: Ratification of the Company's 2025 Earnings Distribution Proposal. (Proposed by the Board of Directors)

Explanation:

1. The Company had net income after tax of NT$ 9,322,825,089 for the year 2025. In

accordance with the Company’s Articles of Incorporation, a proposed earnings distribution table has been prepared (please refer to page 46 of this handbook).

2. It is proposed to allocate NT$ 1,326,853,719 from the distributable earnings of 2025 as cash dividends, representing NT$ 1.75 per share. The total cash dividend shall be calculated to the nearest New Taiwan dollar (with fractional amounts rounded down), and any resulting fractional amounts shall be recognized as other income of the Company. In addition, stock dividends in the amount of NT$ 379,101,070 are proposed (equivalent to NT$ 0.5 per share), representing a distribution of 50 shares for every 1,000 shares held.
3. Upon approval by the shareholders’ meeting, the Board of Directors is authorized to determine the record date for the distribution of dividends and to handle all related matters.
4. The aforementioned cash and stock dividend distribution ratios are calculated based on the number of outstanding shares as of April 2, 2026, totaling 758,202,125 shares (including shares converted from convertible bonds but not yet registered, and after deduction of treasury shares). Should there be any subsequent changes in the number of issued or outstanding shares due to share repurchases, treasury share transfers, employee stock option exercises, conversion of convertible bonds, private placements, or other factors in accordance with applicable laws and regulations, it is proposed that the shareholders’ meeting authorize the Chairman to make corresponding adjustments to the distribution ratios at his discretion.

Resolution:

V. Discussion Items

Proposal 1

Subject: Proposal for the Amendment to the Company's “Articles of Incorporation”. (Proposed by the Board of Directors)

Explanation: In response to the Company’s operational needs, certain provisions of the Articles of Incorporation are proposed to be amended. A comparison table of the amended and original provisions is provided on page 47 of this handbook.

Resolution:

Proposal 2

Subject: Proposal to Release Non-Compete Restrictions for Directors. (Proposed by the Board of Directors)

Explanation:

1. Pursuant to Article 209 of the Company Act, a director who engages, either on the

director's own account or on behalf of another person, in any activity within the scope of the Company's business shall disclose the material details of such activity to the shareholders' meeting and obtain its approval.

2. The newly proposed positions for which the non-competition restrictions on directors are to be lifted are as follows:

Title	Name	Position(s) for which Non-Competition Restrictions are Lifted	Principal Business Activities:
Chairman	Jason Technology Co., Ltd. Representative Wang, Su-Chi	• Legal Representative Director, DuroNax Biotech, Ltd.	• Biologics CDMO
Director	Royal Foods Co., Ltd. Representative: Yeh, Sheng-Wen	• CEO / Associate Vice President, Preclinical R&D Division, Lumosa Therapeutics Co., Ltd. • Legal Representative Director, Shine-On BioMedical Co., Ltd. • Legal Representative Director, Cytoengine Co., Ltd.	• New Drug Development • Antibody-Based Anticancer Therapies, Exosome-Based Anticancer Therapies • New Drug Development
Director	Po Chang Investment Co., Ltd.	• Legal Representative Director, Chia Her Industrial Co., Ltd.	• Textiles and Medical Devices
Director	Po Chang Investment Co., Ltd. Representative: Chen, Chun-Hong	• Legal Representative Director, Mycenax Biotech Inc. • Legal Representative Director, Collins Co., Ltd. • Legal Representative Director, Chia Her Industrial Co., Ltd. • Legal Representative Director, Hi-Clearance Inc.	• Biologics Development and Manufacturing • International Trade and Biotech Investment • Textiles and Medical Devices • Medical Devices
Independent Director	Ho, Mei-Yueh	• Independent Director, Acer Incorporated • Director, Kinpo Electronics, Inc.	• Channel Distribution of Information Technology Products, Software, and Maintenance Services • Wholesale and

Title	Name	Position(s) for which Non-Competition Restrictions are Lifted	Principal Business Activities:
		•Director, Onward Therapeutics, Inc.	Retail of Consumer Electronics, Networking and Communication Products, and Medical Devices •New Drug Research and Development
Independent Director	Ho, Shih-Chun	• Legal Representative Vice Chairman, Trade-Van Information Services Co. • Director, Luo Lih-Fen Holding Co., Ltd. • Chairman, Forcera Materials Co., Ltd. • Chairman, Tradeunited Technology (Shanghai) Limited	• Electronic Data Interchange Services • Facial Skincare Products • Semiconductor Equipment Consumables •Development of Software, Electronic Products, and Network Technologies

Resolution:

Proposal 3

Subject: Proposal for the issuance of new common shares for capital increase out of earnings. (Proposed by the Board of Directors)

Explanation:

1. To strengthen working capital, it is proposed to appropriate NT$ 379,101,070 from the distributable earnings of 2025 as stock dividends to shareholders and to issue 37,910,107 new shares through capitalization, with a par value of NT$10 per share.
2. Based on each shareholder's shareholding ratio as recorded in the shareholders' register on the record date, 50 shares will be distributed without consideration for every 1,000 shares held. Fractional shares less than one share may be combined by shareholders within 5 days from the book closure date by applying through the Company's stock affairs agent to form whole shares. Any remaining fractional shares that cannot be consolidated into whole shares shall be settled in cash at par value, calculated to the nearest New Taiwan dollar (with fractional amounts rounded down). Such fractional shares are proposed to be authorized for subscription by

specific persons designated by the Chairman at par value, subject to approval by the shareholders' meeting. For shareholders participating in book-entry distribution, any cash amounts attributable to fractional shares of less than one share shall be applied as handling fees for the book-entry process.

3. Upon approval by the shareholders' meeting and obtaining approval from the competent authority, it is proposed that the Board of Directors be authorized to determine the record date for the capital increase.
4. The capital increase plan and any matters not addressed herein are proposed to be authorized to the Board of Directors for full discretion in accordance with applicable laws and regulations.
5. The rights and obligations of the newly issued shares shall be identical to those of the existing shares.
6. The aforementioned payout ratio is calculated based on the number of outstanding shares as of April 2, 2026, totaling 758,202,125 shares (including shares converted from convertible bonds but not yet registered, and after deduction of treasury shares). Should there be any subsequent changes in the number of issued or outstanding shares due to share repurchases, treasury share transfers, employee stock option exercises, conversion of convertible bonds, private placements, or other factors in accordance with applicable laws and regulations, it is proposed that the shareholders' meeting authorize the Chairman to make corresponding adjustments to the payout at his discretion.

Resolution:

Proposal 4

Subject: Proposal for the issuance of new common shares by private placement in cash. (Proposed by the Board of Directors)

Explanation:

1. To strengthen working capital, repay borrowings, and invest in the biotechnology industry, and after taking into consideration timeliness, convenience, and issuance costs, the Company proposes to conduct a private placement of common shares through a cash capital increase.
2. The total number of shares to be issued under this private placement shall not exceed 30,000,000 shares and is expected to be carried out in two tranches within one year from the date of resolution by the shareholders' meeting.
3. In accordance with Article 43-6 of the Securities and Exchange Act and the "Directions for Public Companies Conducting Private Placements of Securities," the relevant details of the private placement are as follows:
   (1) Basis for and reasonableness of the pricing:

The reference price for the private placement shall be determined based on the higher of the following two calculations:

A. The simple average closing price of the Company's common shares for either 1, 3, or 5 business days prior to the pricing date, adjusted for stock dividends, cash dividends, and capital reduction.

B. The simple average closing price of the Company's common shares for the 30 business days prior to the pricing date, adjusted for ex-rights, ex-dividend, and capital reduction.

The private placement price shall not be less than 80% of the reference price. The pricing methodology complies with applicable laws and regulations and is considered reasonable. The actual pricing date and subscription price, within the range approved by the shareholders' meeting, are proposed to be authorized to the Board of Directors for determination based on negotiations with specific persons and prevailing market conditions.

(2) Selection of specific persons, purpose, necessity, and expected benefits:

The offerees will be limited to specific persons in accordance with Article 43-6 of the Securities and Exchange Act and related regulations, and will be selected primarily from strategic investors. The Board of Directors is authorized to identify and negotiate with such specific persons. To support the Company's future development, improve its financial structure, and enhance profitability, it is necessary to introduce strategic partners that can contribute to the Company's operations. Through their experience, technology, and expertise, such partners are expected to enhance operating performance and support the Company's long-term growth.

(3) Necessity of the private placement:

A. Reasons for not adopting a public offering: Considering the timeliness, convenience, and cost of issuance, a private placement provides a more efficient means of raising capital. In addition, the statutory restriction on transfer within three years helps maintain a stable long-term relationship with strategic investors.

B. Number of shares to be issued: No more than 30,000,000 ordinary shares, and the shares will be issued twice within one year respectively from the date of the resolution of the shareholders' meeting. No more than 15,000,000 shares for the first issuance, and no more than 15,000,000 shares for the second issuance.

C. Purpose of private placement: The two private placements are used to replenish working capitals, repay borrowings and invest in the biotechnology industry.

D. Expected benefits: The expected benefits from the two private placements are to strengthen financial structure and improve operating efficiency as well as corporate competitiveness.

4. Rights and obligations of the privately placed shares:
The rights and obligations of the privately placed common shares shall be the same as those of the Company's existing common shares. However, in accordance with the Securities and Exchange Act, such shares may not be transferred within three years from the date of delivery, except to permitted transferees as specified by law. After the expiration of the three-year period, the Board of Directors is authorized to apply to the competent authority for public issuance and listing (or OTC trading) in accordance with applicable regulations.
5. The main terms of the private placement plan, including the actual issue price, number of shares, issuance conditions, pricing date, capital increase record date, project items, total amount to be raised, expected schedule, and anticipated benefits, as well as all other related matters, will be determined by the Board of Directors based on market conditions. In the event of any regulatory changes, instructions from competent authorities, or adjustments required due to operational or market conditions, the Board of Directors is authorized to make such amendments accordingly.
6. To facilitate the private placement, the Chairman, or a person designated by the Chairman, is authorized to execute and negotiate all agreements and documents related to the private placement and to handle all related matters on behalf of the Company.
7. Impact of the private placement on the Company's managerial control: The Company's managerial control is stable; therefore, the private placement is not expected to have a material impact on the Company's managerial control.
8. Any matters not addressed herein shall be handled by the Board of Directors in accordance with applicable laws and regulations.

Resolution:

VI. Extemporary Motions

VII. Meeting Adjourned

Chapter 3. Attachments

I. 2025 Business Report

(I) Business Strategy and Implementation Status

The Company is committed to becoming the most professional biotechnology investment holding company in Taiwan. Through deep incubation of its core businesses, as well as strategic investments and mergers and acquisitions, it aims to advance its core businesses onto the international stage. The Company's investment activities are organized into three major segments: (1) large-scale investments with low risk and stable returns; (2) strategic investments featuring high technology, high growth potential, and higher risk; and (3) investments in emerging industries with future growth potential. These three segments are mutually reinforcing and are supported by a sound financial structure and stable cash flows. On this basis, the Company continues to strengthen its core businesses while simultaneously developing a second growth curve. The following outlines representative companies within each segment and their strategic positioning:

1. Large-Scale Investments with Low Risk and Stable Returns:
   (1) Core Businesses: Including Center Laboratories, Mycenax, Glac Biotech, TOT BIOPHARM, KriSan, Lumosa, BaoPharma, BioGend, Medeon, among others. The Company is deeply involved in their operations, with the goal of advancing its core businesses onto the global stage in 2025 while generating strong cash flows.
   (2) Large Pharmaceutical Funds: The Company focuses on investments in large-scale funds with low risk and strong cash flow generation (e.g., GL Capital and Vivo Capital). Stable returns from these investments contribute to cash inflows and help maintain a sound financial structure for the Group.
2. Strategic Investments with High Technology, High Growth, and Higher Risk: These investments focus on biotechnology opportunities that can generate synergies with the Company's core businesses, thereby progressively strengthening their competitiveness in specialized segments.
3. Investments in Emerging Industries: Through a combination of fund investments and direct investments, the Company explores opportunities in emerging sectors, laying the foundation for a second growth curve to support its long-term development.

The Company's consolidated revenue for 2025 amounted to NT$1,516 million, representing a decrease of 6.28% compared with the previous year. In the pharmaceutical business, revenue declined due to weaker demand, primarily attributable to a decline in patient visits for upper respiratory tract infections in Taiwan in 2025. In response, the Company has actively adjusted its product portfolio to focus on high-margin central nervous system and geriatric medications, while accelerating market expansion. At the same time, cost-reduction and efficiency-enhancement initiatives have been launched at the manufacturing level to improve operational efficiency and strengthen the profit structure. These measures are expected to support improved operating performance in 2026. With respect to the wholly owned subsidiary Glac Biotech, overall revenue declined in

2025 due to delays in cross-border shipments. However, the aforementioned factors gradually eased in the second half of the year, and visibility of international orders continued to improve, providing room for a recovery in revenue momentum. In the investment segment, performance in 2025 was excellent. Benefiting from a recovery in the Hong Kong equity market and the successful listing of BaoPharma in Hong Kong, the valuation of financial assets increased, resulting in the recognition of non-operating income of NT$11,930 million for the year, and net income after tax of NT$9,323 million. The following provides an overview of the operating performance of the core businesses in 2025:

- **Center Laboratories**

Center Laboratories is a leading brand in liquid pharmaceutical formulations in Taiwan. In 2025, full-year revenue reached NT$941 million, with annual sales volume totaling 33.64 million bottles. Among these, revenue from central nervous system (CNS) medications amounted to NT$295 million, while non-CNS medications generated NT$646 million, demonstrating steady growth momentum. Looking ahead, the Company will continue to deepen the development of geriatric liquid formulations and, in response to government policies, actively expand into the long-term care market, which has strong growth potential.

As market demand continues to rise, the Company is also accelerating its capacity expansion plans and optimizing capacity allocation to ensure stable supply and further strengthen its competitive advantages.

- **Glac Biotech**

Glac Biotech Co., Ltd. (hereinafter referred to as “Glac Biotech”) is a leading company focused on functional probiotics and postbiotics-related products and technologies. In 2025, it expanded in both domestic and international markets. As global demand for probiotics and postbiotics in health applications continues to grow, the Company has undertaken the following initiatives:

1. Expanded collaboration with domestic and international distribution channels, as well as B2B OEM/ODM partnerships, to enhance market penetration.
2. Actively participated in international biotechnology exhibitions and professional forums, showcasing innovative R&D achievements in products targeting gut health and brain health.
3. Continued to expand its product portfolio into animal and plant health, sports nutrition, and applications for specific population groups, thereby enhancing overall product competitiveness.

- **Mycenax**

Mycenax is the only company in Taiwan 100% dedicated to biologics CDMO services. In 2025, it successfully passed inspections by multiple regulatory authorities, including the European Medicines Agency (EMA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and was officially qualified as a supplier for two internationally marketed biologic products, providing a stable foundation for future operational growth.

Building on years of deep engagement in the Japanese market, Mycenax, together with three Japanese companies, Alfresa, Kidswell, and Chiome, established a joint venture, Alfenax Biologics, to develop a biologics manufacturing base in Japan and to conduct biologics CMO and pharmaceutical distribution businesses. At the same time, Mycenax continues to implement its "Big D and Medium M" brand positioning and is actively expanding into the development of emerging antibody-drug conjugates (ADCs). Through strategic collaboration with Japanese ADC companies, it aims to establish a competitive, next-generation one-stop ADC service platform.

- **KriSan**

KriSan Biotech continues to focus on high technical barrier CDMO (contract development and manufacturing organization) services. Since 2023,KriSan has actively expanded its customer base in small molecule drugs and antibody-drug conjugates (ADCs), while simultaneously advancing facility optimization initiatives. By 2024, KriSan had successfully completed the full build-out and commenced mass production at its ADC GMP manufacturing facilities (covering both linker-payload and drug substance capabilities). It has delivered more than 50 ADC CDMO projects, supporting both preclinical and clinical-stage products, and has progressively established a comprehensive one-stop ADC CDMO service model.

Leveraging its proprietary linker-payload library, KriSan is able to rapidly provide flexible and high-quality solutions, including next-generation linkers and the development of multi-arm linkers capable of conjugating dual or multiple payloads. This advantage not only expands market reach, but also facilitates the establishment of early-stage partnerships with clients, thereby enhancing conversion into subsequent GMP CDMO services.

In 2025, the company undertook nearly 40 contract development projects. The small molecule business continued to grow steadily, accounting for approximately 90% of total revenue. Batch production for clients' Phase III clinical trials and commercial-scale manufacturing has been successfully completed. Inspections by international regulatory authorities are expected in 2027, marking the transition into commercial-scale manufacturing. The ADC business accounted for approximately 10% of total revenue, primarily derived from early-stage development projects. It is expected to enter process scale-up and IND-stage GMP production in 2026, with the potential to contribute more than 60% of total revenue. In the area of emerging conjugated drugs (XDCs), the company has also begun providing preclinical samples to support clients in drug candidate screening.

In terms of international collaboration, the company continues to deepen its presence in Japan, Europe, and the United States. In April 2025, KriSan signed a memorandum of understanding (MOU) with CMIC Bio, a subsidiary of Japan's CMIC Group, to jointly expand the ADC market in Japan. At the same time, it continues its strategic alliance with Mycenax Biotech to expand into Japan, Europe, and the United States, forming a strategic alliance to build a one-stop ADC CDMO platform in Asia.

- **Lumosa**

Lumosa adheres to its "reSEARCH & DEVELOPMENT" model, focusing on the development of drug candidates with strong scientific rationale and high R&D potential. Through project-based execution, it effectively shortens new drug development timelines and optimizes resource allocation, while actively advancing international strategic alliances, licensing, and co-development to reduce risk and accelerate time to market.

LT3001, a novel drug for acute ischemic stroke, reached a key milestone in 2025. The Phase II clinical trial (LT3001-202), led by Shanghai Pharmaceuticals in China, and the Phase II clinical trial (LT3001-205), led by Lumosa across the United States, Europe, and Taiwan, were both successfully completed. The trial results were presented at the World Stroke Congress (WSC) in Barcelona at year-end. The data showed that, when administered within a 24-hour treatment window, LT3001, whether used in combination with mechanical thrombectomy or as a standalone multi-dose regimen, did not increase the risk of intracranial hemorrhage. In addition, among patients with moderate-to-severe and disabling stroke, LT3001 demonstrated an increased proportion of patients achieving functional independence (mRS 0–2) at 90 days. Safety and efficacy trends were consistent across different ethnic groups, providing support for subsequent global Phase III development. With respect to the subsequent clinical strategy, the team has conducted regulatory consultation meetings with the U.S. Food and Drug Administration (FDA), which provided positive feedback on the Phase III trial design of LT3001. Important consensus was also reached regarding the design and regulatory pathway for global Phase III clinical trials. Key technical aspects of the clinical trials were confirmed during these meetings, which will help shorten the timeline for future regulatory approval. In terms of intellectual property, LT3001 has obtained formulation patents in 17 countries, including the United States, China, and Europe, with patent protection extending to 2040. Method-of-use patents have also been filed, which are expected to extend protection to 2042.

Lumosa continues to strengthen its innovative therapeutic platform. Together with Center Laboratories, it has invested in Cytoengine to introduce CAR-T (chimeric antigen receptor T-cell) technology to enhance its platform. It has also invested in GenEditBio, a company focused on innovative gene editing technologies, and continues to develop LT6001, a stem cell-derived exosome drug for neurological diseases, advancing new therapeutic approaches in neurology.

- **BioGend**

BioGend Therapeutics is a regenerative medicine specialist focused on orthopedics and infectious diseases. In 2025, full-year revenue reached NT$220 million, representing a year-on-year increase of 32%. The progress of its major products is as follows:

1. RevoCart: In the domestic market, the product has been adopted by a large number of medical institutions and physicians, with over a thousand successful surgical cases accumulated. Sales have grown steadily and continue to contribute sustainable cash flows. In overseas markets, medical device approvals have been obtained in Cambodia, Thailand, the Philippines, Malaysia, Singapore, and Hong Kong. Local distributors have been engaged to advance market expansion, and initial shipments to overseas

markets have been completed. For international licensing, BioGend is actively pursuing licensing partnerships in major markets including Europe, the United States, and Japan, with the aim of bringing RevoCart to the global market.

2. Osteogenic Inductive Factor (OIF): Results from feasibility studies for open tibial fractures in Taiwan and the United States have been announced, demonstrating the product's efficacy. BioGend plans to proceed with Phase III clinical trials for OIF to accelerate commercialization. Based on Phase II clinical data for nonunion fractures in Japan and open tibial fractures in Taiwan and the United States, BioGend will simultaneously engage with international partners in Europe and the United States to pursue licensing collaborations.
3. Sales of anti-infective products, including Minocycline, have grown steadily and continue to contribute sustainable cash flows, while Fluzole has received approval for a change to its drug license and, following its launch, is contributing to revenue.

- **Medeon**

Medeon Biodesign specializes in the R&D and manufacturing of high-value, advanced medical devices. At its current stage, its operations are focused on two main areas. In addition to its long-established experience in the incubation of innovative medical devices, it has expanded into the contract development and manufacturing (CDMO) business for advanced medical devices. Through a series of strategies, including acquisitions and internal integration, it is building a highly efficient and technologically advanced CDMO platform.

1. CDMO Business: Medeon's subsidiary, Medeologix, focuses on the contract development and manufacturing (CDMO) of advanced medical devices. Its core business includes high-end balloons, catheters, and the assembly of medical device components and finished products. In 2025, leveraging its high-quality manufacturing capabilities and efficient development services, Medeologix achieved strong growth in both its customer base and order intake, while maintaining its rapid revenue growth trajectory. It has also successfully implemented a cross-border operating model of "order intake and pilot production in the United States, and large-scale manufacturing in Taiwan."
2. Innovative Medical Device Development and Incubation: Urocross, a minimally invasive treatment device for benign prostatic hyperplasia, announced preliminary results in May 2025 from its U.S. IDE pivotal clinical trial, demonstrating favorable safety and efficacy. Based on data from this 240-patient pivotal study, a marketing application was submitted to the U.S. Food and Drug Administration (FDA) in November 2025. Duett, a thoracic aortic repair device, initiated an IDE clinical trial in the United States in 2024 and successfully enrolled its first patient. Progress has been in line with expectations, and in 2025, the study received FDA approval to proceed to the second stage of clinical trials. The total planned enrollment is approximately 70 patients, and enrollment is ongoing.

- **BaoPharma**

BaoPharma is dedicated to the development of next-generation biologics with high technical barriers. It aims to become a leader in replacing biochemically extracted products with genetically engineered alternatives, a pioneer in recombinant enzyme- and antibody-based combination products and gene therapy, and a leader in the assisted reproduction segment. On December 10, 2025, BaoPharma was officially listed on the Main Board of The Hong Kong Stock Exchange, marking a new stage in its entry into the international capital markets.

Major product developments in 2025:

1. IgG-degrading enzyme: The first IgG-degrading enzyme globally with low pre-existing antibody levels to enter Phase III clinical trials. It targets a range of diseases driven by pathogenic IgG, including kidney transplant desensitization, anti-GBM disease, and Guillain–Barré syndrome (GBS), with potential for repeat dosing and functional cure.
2. Recombinant human hyaluronidase: The first recombinant human hyaluronidase in China to submit a New Drug Application (NDA). Through broad collaborations with global pharmaceutical companies, it enables large-volume subcutaneous administration of antibody drugs and antibiotics.
3. Long-acting follicle-stimulating hormone: Slonva® was approved for marketing in August 2025, becoming the first approved long-acting follicle-stimulating hormone in China. It is designed to reduce injection frequency while improving safety and patient compliance.

(II) Operating Results and Budget Execution Status

In 2025, the Company’s consolidated net operating revenue amounted to NT$1,516,190 thousand, representing a decrease of NT$101,679 thousand, or 6.28%, compared with NT$1,617,869 thousand in 2024. Consolidated net income after tax was NT$9,322,825 thousand, representing an increase of NT$10,426,233 thousand, or 944.91%, compared with a consolidated net loss after tax of NT$1,103,408 thousand in 2024.

For the same period, the Company’s standalone net operating revenue amounted to NT$941,103 thousand, representing a decrease of NT$30,607 thousand, or 3.15%, compared with NT$971,710 thousand in 2024. Standalone net income after tax was NT$9,322,825 thousand, representing an increase of NT$10,426,508 thousand, or 944.70%, compared with a standalone net loss after tax of NT$1,103,683 thousand in 2024.

(III) Analysis of Financial Results and Profitability

1.Consolidated Financial Results

Unit: NT$ thousand

Item	2024	2025
Operating revenue	1,617,869	1,516,190
Gross profit	748,953	621,258
Operating expenses	514,893	533,995
Operating income (loss)	234,060	(361,621)
Non-operating income and expenses	(1,404,094)	11,930,258
Net income (loss) before tax	(1,170,034)	11,568,637
Net income (loss) after tax	(1,103,408)	9,322,825
Earnings per share (NT$)	(1.48)	12.33

2.Consolidated Profitability

Unit: %

Item	2024	2025
Return on assets	(3.50)	31.53
Return on equity	(5.83)	41.86
Pre-tax profit as a percentage of paid-in capital	(16.13)	151.97
Profit margin	(68.20)	614.88
Earnings per share (NT$)	(1.48)	12.33

3.Standalone Financial Results

Unit: NT$ thousand

Item	2024	2025
Operating revenue	971,710	941,103
Gross profit	509,307	464,825
Operating expenses	324,474	357,468
Operating income (loss)	184,833	(341,527)
Non-operating income and expenses	(1,343,304)	11,889,796
Net income (loss)	(1,158,471)	11,548,269

before tax		
Net income (loss) after tax	(1,103,683)	9,322,825
Earnings per share (NT$)	(1.48)	12.33

4.Standalone Profitability

Unit: %

Item	2024	2025
Return on assets	(3.64)	32.12
Return on equity	(5.83)	41.86
Pre-tax profit as a percentage of paid-in capital	(15.97)	151.70
Profit margin	(113.58)	990.62
Earnings per share (NT$)	(1.48)	12.33

(IV) Research and Development

1.Advanced overseas market expansion by obtaining marketing approval in Hong Kong in March 2025 for an anti-allergy and asthma product.

2.Obtained marketing approval in May 2025 for a drug for neuropathic pain and as an adjunctive treatment for epilepsy.

3.Completed phased development of new liquid formulations for an anticoagulant and an anti-diabetic drug.

4.Continued development of a drug for neonatal and pediatric heart failure, obtained approval for contract manufacturing in April 2025, received recognition under the Ministry of Health and Welfare's "2025 Optimized Pediatric Healthcare Plan," and obtained marketing approval in May 2025.

5.Completed new product development evaluation for two drugs for the treatment of pediatric autoimmune diseases, and plans to initiate development of one generic drug in 2026.

6.Completed the development evaluation of a new drug for adjunctive treatment of Parkinson's disease, and plans in 2026 to conduct an evaluation for exemption from bridging clinical trials for a new chemical entity and obtain the relevant approval.

7.Conducted development of a generic drug for the treatment of depression and anxiety.

8.Continued screening and evaluation of new product development opportunities addressing unmet prescription needs in Taiwan.

Chairperson: Wang, Su-Chi　　Managerial Officer: Hsu, Jui-Pao　　Accountng Officer: Mao, An-Ni

II. 2025 Audit Committee’s Review Report

Center Laboratories, Inc.

Audit Committee’s Review Report

The Board of Directors has prepared the Company's 2025 Parent Company Only Financial Statements and Consolidated Financial Statements which have been audited and certified by CPAs Cheng, Chung-Hao and Chi, Chia-Yu of Full-Fill & Co., CPAs. Together with the Business Report and the proposal for earnings distribution, the aforementioned documents have been reviewed by this Committee, and no material nonconformities were identified. Pursuant to Article 14-4 of the Securities and Exchange Act and Article 219 of the Company Act, this report is hereby prepared and respectfully submitted for your review.

Sincerely,

Center Laboratories, Inc. 2026 Annual Shareholders' Meeting

Convener of the Audit Committee: Ho, Mei-Yueh

April 14, 2026

III. 2025 Details of Directors' Remuneration

Unit: NT$ thousand; December 31, 2025

Title	Name	Director Remuneration								Total of A, B, C, and D and Percentage of Net Income After Tax (%)		Remuneration Received Concurrently as Employees								Total of A, B, C, D, E, F, and G and Percentage of Net Income After Tax (%)		Remuneration Received from Investee Companies (Excluding Subsidiaries) or the Parent Company
		Remuneration (A)		Severance or Pension (B)		Directors' Compensation (C)		Business Execution Expenses (D)				Salary, Bonuses, and Special Allowances (E) (Note 5)		Severance or Pension (F)		Employees' Compensation (G) (Note 6)						
																The Company		All Companies Included in the Financial Statements				
		The Company	All Companies Included in the Financial Statements	The Company	All Companies Included in the Financial Statements	The Company	All Companies Included in the Financial Statements	The Company	All Companies Included in the Financial Statements	The Company	All Companies Included in the Financial Statements	The Company	All Companies Included in the Financial Statements	The Company	All Companies Included in the Financial Statements	Cash Amount	Share-based Amount	Cash Amount	Share-based Amount	The Company	All Companies Included in the Financial Statements (%)	
Chairman	Jason Technology Co., Ltd.	0	0	0	0	3, 649	3, 649	0	0	3, 649 0. 04%	3, 649 0. 04%	0	0	0	0	0	0	0	0	3, 649 0. 04%	3, 649 0. 04%	0
	Representative: Wang, Su-Chi	0	0	0	0	0	0	50	50	50 0. 0005%	50 0. 0005%	5, 862	5, 862	0	0	434	0	434	0	6, 346 0. 07%	6, 346 0. 07%	94
Director	Tsai, Chang-Hai	0	0	0	0	1, 825	1, 825	35	35	1, 860 0. 02%	1, 860 0. 02%	0	0	0	0	0	0	0	0	1, 860 0. 02%	1, 860 0. 02%	0
Director	Chang, Po-Chih	0	0	0	0	1, 825	1, 825	50	50	1, 875 0. 02%	1, 875 0. 02%	0	0	0	0	0	0	0	0	1, 875 0. 02%	1, 875 0. 02%	1, 723
Director	Lejean Biotech Co., Ltd.	0	0	0	0	1, 825	1, 825	0	0	1, 825 0. 02%	1, 825 0. 02%	0	0	0	0	0	0	0	0	1, 825 0. 02%	1, 825 0. 02%	0
	Representative: Lin, Chia-Ling	0	0	0	0	0	0	45	45	45 0. 0005%	45 0. 0005%	1, 540	1, 540	74	74	269	0	269	0	1, 928 0. 02%	1, 928 0. 02%	40
Director	Royal Foods Co., Ltd. (Note 1)	0	0	0	0	945	945	0	0	945 0. 01%	945 0. 01%	0	0	0	0	0	0	0	0	945 0. 01%	945 0. 01%	0
	Appointed Representative: Yeh, Sheng-Wen	0	0	0	0	0	0	15	15	15 0. 0002%	15 0. 0002%	0	0	0	0	0	0	0	0	15 0. 0002%	15 0. 0002%	4, 191

Title	Name	Director Remuneration								Total of A, B, C, and D and Percentage of Net Income After Tax (%)		Remuneration Received Concurrently as Employees								Total of A, B, C, D, E, F, and G and Percentage of Net Income After Tax (%)		Remuneration Received from Investee Companies (Excluding Subsidiaries) or the Parent Company
		Remuneration (A)		Severance or Pension (B)		Directors' Compensation (C)		Business Execution Expenses (D)				Salary, Bonuses, and Special Allowances (E) (Note 5)		Severance or Pension (F)		Employees' Compensation (G) (Note 6)						
																The Company		All Companies Included in the Financial Statements				
		The Company	All Companies Included in the Financial Statements	The Company	All Companies Included in the Financial Statements	The Company	All Companies Included in the Financial Statements	The Company	All Companies Included in the Financial Statements	The Company	All Companies Included in the Financial Statements	The Company	All Companies Included in the Financial Statements	The Company	All Companies Included in the Financial Statements	Cash Amount	Share-based Amount	Cash Amount	Share-based Amount	The Company	All Companies Included in the Financial Statements (%)	
Director	Po Chang Investment Co., Ltd.	0	0	0	0	1,825	1,825	0	0	1,825 0.02%	1,825 0.02%	0	0	0	0	0	0	0	0	1,825 0.02%	1,825 0.02%	0
Director	Appointed Representative: Chen, Chun-Hong	0	0	0	0	0	0	45	45	45 0.0005%	45 0.0005%	0	0	0	0	0	0	0	0	45 0.0005%	45 0.0005%	40
Director	Wechen Co., Ltd. (Note 2)	0	0	0	0	880	880	30	30	910 0.01%	910 0.01%	0	0	0	0	0	0	0	0	910 0.01%	910 0.01%	0
Independent Director	Ho, Mei-Yueh	600	600	0	0	1,825	1,825	100	100	2,525 0.03%	2,525 0.03%	0	0	0	0	0	0	0	0	2,525 0.03%	2,525 0.03%	0
Independent Director	Ho, Shih-Chun	600	600	0	0	1,825	1,825	95	95	2,520 0.03%	2,520 0.03%	0	0	0	0	0	0	0	0	2,520 0.03%	2,520 0.03%	21
Independent Director	Kuo, Li-Wei (Note 1)	300	300	0	0	945	945	25	25	1,270 0.01%	1,270 0.01%	0	0	0	0	0	0	0	0	1,270 0.01%	1,270 0.01%	0

Note ：(1) Appointed on June 26, 2025.

(2) Relieved of duties on June 26, 2025.

IV. Status of Issuance of the 8th and 9th Domestic Unsecured Convertible Corporate Bonds

To repay bank borrowings and support reinvestment, the Company issued the Eighth and Ninth Domestic Unsecured Convertible Bonds. The principal terms and relevant details are as follows:

Item	Domestic 8th unsecured convertible bonds	Domestic 9th unsecured convertible bonds
Date of Board Resolution	March 3, 2026	March 3, 2026
Approval Reference No. from Competent Authority	The Company was filed and effective through the Financial Supervisory Commission authorization No.1150336227 dated on March 30, 2026.	The Company was filed and effective through the Financial Supervisory Commission authorization No. 11503362271 dated on March 30, 2026.
Issue date	May 4, 2026.	May 14, 2026.
Par value	NT$100,000	NT$100,000
Issue price	Issued at 100% of par value	The bonds shall be issued at no less than 100% of their face value, with the actual issuance price determined by the results of the competitive auction.
Total issue amount	NT$1,500,000,000	NT$500,000,000
Coupon rate	0%	0%
Term	5 years; maturity date: May 4, 2031	5 years; maturity date: May 14, 2031
Repayment method	Redeemed in cash at par value upon maturity	Redeemed in cash at par value upon maturity
Outstanding principal	NT$1,500,000,000	NT$500,000,000
Redemption or early repayment terms	Refer to the issuance and conversion terms of the Company's domestic 8th unsecured convertible bonds	Refer to the issuance and conversion terms of the Company's domestic 9th unsecured convertible bonds
Conversion price at issuance	NT$ 43	NT$ 42
Current conversion price	NT$ 43	NT$ 42
Conversion period	August 5, 2026 to May 4, 2031	August 15, 2026 to May 14, 2031
Amont converted into common shares	None	None

V. 2025 Parent Company Only Financial Statements

Independent Auditors' Report

The Board of Directors and Shareholders of Center Laboratories, Inc.

Opinion

We have audited the accompanying parent company only financial statements of Center Laboratories, Inc. (the "Company"), which comprise the parent company only balance sheets as of December 31, 2025 and 2024, and the parent company only statements of comprehensive income, changes in equity and cash flows for the years then ended, and notes to the parent company only financial statements, including a summary of material accounting policies.

In our opinion, based on our audits and the report of another auditor (please refer to the Other Matter paragraph), the accompanying parent company only financial statements present fairly, in all material respects, the parent company only financial position of the Company as of December 31, 2025 and 2024, and its parent company only financial performance and its parent company only cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Parent Company Only Financial Statements section of our report. We are independent of the Company in accordance with The Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. Based on our audits and the report of another auditor, we believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the parent company only financial statements for the year ended December 31, 2025. These matters were addressed in the context of our audit of the parent company only financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matters for the Company's parent company only financial statements for the year ended December 31, 2025 are stated as follows:

Evaluation of financial instruments

Refer to Note 4(5) of the parent company only financial statements for the accounting policies. Refer to Note 5(5) of the parent company only financial statements for the significant accounting assumptions, judgments and major sources of estimation uncertainty. Refer to Note 6(25) of the parent company only financial statements for the details on the fair value measurement of the financial instrument, the level, valuation technique, and inputs.

As of December 31, 2025, the amount of financial assets (liabilities) at fair value through profit or loss were material to the parent company only financial statements as a whole. Furthermore, the financial instruments are measured based on Level 3 inputs whose quoted prices are unobservable and relies on managerial judgment and assumptions. As a result, financial assets at fair value through profit or loss and the measurement is determined as a key audit matter. The main audit procedures we have performed in respect of the key audit matter stated above were as follows:

1. We selected appropriate samples from the details of the purchase of financial assets at fair value through profit or loss as of 2025, and examined original vouchers, bank statements, and investment appraisal reports thereof.
2. Confirmation letters stating the account balance of financial assets at fair value through profit and loss as of December 31, 2025 were issued to verify the existence of these accounts.
3. We obtained asset valuation report from independent expert outsourced by the Company to understand the evaluation model and parameters used in the measurement of the financial instruments and recalculated the fair value of selected samples of the financial instruments.

Assessment of investment accounted for using the equity method

Center Laboratories, Inc. currently focuses its operations on the “Industry Investment of the Biotechnology and Healthcare”, and owns many invested companies in the fields of new drug development, medical devices, and the healthcare industries.

Since the assessment of investment accounted for using the equity method with material amounts involves relatively complex calculation and takes significant audit manpower, the assessment of investment accounted for using the equity method was identified as a key audit matter.

Refer to Note 4(7) of the parent company only financial statements for accounting policies. Refer to Note 6(6) of the parent company only financial statements for the disclosure of carrying amount of investment accounted for using the equity method. The audit procedures we have performed in respect of the key audit matter stated above were as follows:

1. We issued instruction referral letters to review invested companies’ audited financial statements and recalculated the investment profit and loss and account balance of the invested companies based on shareholding ratio to confirm accuracy.
2. We sent confirmation letters to verify long-term equity investment information.

3. Where any deficiency occurred to an invested company, we took action to understand the main reason for the deficiency and inquired whether there is concern for continued operations and future countermeasures.
4. We reviewed reasonableness of the management staff's explanation on the assessment document of asset impairment.
5. We ascertained whether the invested company's operation still continues; if not, whether the ceased operation was properly adjusted or disclosed.

Other Matter

For the aforesaid invested companies accounted for using the equity method disclosed in the parent company only financial statements for the year ended December 31, 2025 and 2024, the financial statements of BioGend Therapeutics Co., Ltd., Lumosa Therapeutics Co., Ltd., Medeon Biodesign, Inc., TOT BIOPHARM International Compay Limited, A2 + Healthcare Venture Fund L.P., Fangyuan Growth SPC., ANYA BIOPHARM INC., Glac Biotech Co., Ltd., Bioflag International Corporation, and Cytoengine Co., Ltd. were not audited by the Company's CPA. Those financial statements were audited by another auditor whose reports have been thereon furnished to us, and our opinions expressed herein, insofar as it relates to the amounts included in the financial statements, are based solely on the report of other auditor. These investments accounted for using the equity method amounted to NT$6,422,351 thousand and NT$5,641,224 thousand, constituting 18.8% and 22.7% of the total assets as of December 31, 2025 and 2024, respectively. The share of loss from subsidiaries and associates accounted for using the equity method amounted to NT$113,911 thousand and NT$430,587 thousand, constituting (1.0)% and (37.2)% of the (loss) before income tax for the years ended December 31, 2025 and 2024, respectively.

Responsibilities of Management and Those Charged with Governance for the Parent Company Only Financial Statements

Management is responsible for the preparation and fair presentation of the parent company only financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and for such internal control as management determines is necessary to enable the preparation of parent company only financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company only financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the Audit Committee, are responsible for overseeing the Company's financial reporting process.

Auditors' Responsibilities for the Audit of the Parent Company Only Financial Statements

Our objectives are to obtain reasonable assurance about whether the parent company only financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these parent company only financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the parent company only financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the parent company only financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the parent company only financial statements, including the disclosures, and whether the parent company only financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

6. Obtain sufficient and appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the parent company only financial statements. We are responsible for the direction, supervision, and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the parent company only financial statements for the year ended December 31, 2025 and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audits resulting in this independent auditors' report are Cheng, Chung-Hao and Chi, Chia-Yu.

Ful-Fill & Co., CPAs

Taipei, Taiwan

Republic of China

March 3, 2026

Notice to Readers

The accompanying parent company only financial statements are intended only to present the financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such parent company only financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' report and the accompanying parent company only financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' report and parent company only financial statements shall prevail.

Center Laboratories, Inc.

Parent Company Only Balance Sheets

As of December 31, 2025 and 2024

In Thousands of New Taiwan Dollars

Account Code	Assets	Notes	December 31, 2025 Amount	%	December 31, 2024 Amount	%
11XX	Current assets					
1100	Cash and cash equivalents	6(1)	$ 103,114	—	$ 1,184,234	5
1110	Financial assets at fair value through profit or loss	4, 6(2)	235,304	1	231,206	1
1136	Financial assets at amortized cost	4, 6(3)	—	—	347,521	1
1150	Notes receivable, net		19,569	—	22,846	—
1170	Accounts receivable, net	4, 6(4)	140,637	—	145,427	—
130X	Inventories	4, 6(5)	203,521	1	158,385	1
1476	Other financial assets	8	311,384	1	1,178,939	5
1470	Other current assets	7	15,623	—	26,613	—
11XX	Total current assets		1,029,152	3	3,295,171	13
15XX	Non-current assets					
1510	Financial assets at fair value through profit or loss	4, 6(2), 8	8,053,348	24	8,038,792	32
1535	Investments accounted for using the equity method	4, 6(6), 7, 8	23,651,545	69	12,289,576	50
1550	Property, plant and equipment	4, 6(7), 8	874,960	3	589,577	2
1600	Right-of-use assets	4, 6(8)	325	—	1,301	—
1755	Investment properties, net	4, 6(9), 8	466,370	1	662,247	3
1760	Intangible assets	4	4,317	—	4,133	—
1780	Refundable deposits		9,079	—	6,348	—
1920	Prepayment for equipment	9	5,438	—	2,647	—
1915	Net defined benefit asset	4, 6(12)	19,771	—	13,524	—
1975	Total non-current assets		33,085,153	97	21,608,145	87
1XXX	Total assets		$ 34,114,305	100	$ 24,903,316	100

Account Code	Liabilities and Equity	Notes	December 31, 2025 Amount	%	December 31, 2024 Amount	%
21XX	Current liabilities					
2100	Short-term loans	6(10), 8	$ 750,000	2	$ 900,000	4
2120	Financial liabilities at fair value through profit or loss	4, 6(2)	12,794	—	—	—
2130	Contract liabilities	6(17)	117,697	1	97,291	—
2170	Accounts payable		96,083	—	108,157	1
2200	Other payables	7	105,658	—	80,074	—
2230	Current tax liabilities		78,680	—	257,865	1
2320	Long-term liabilities, current portion	6(10), 6(11), 8	1,860,210	6	2,584,704	10
2399	Other current liabilities	7	11,773	—	16,395	—
21XX	Total current liabilities		3,032,895	9	4,044,486	16
25XX	Non-current liabilities					
2500	Financial liabilities at fair value through profit or loss	4, 6(2)	—	—	46,158	—
2530	Bonds payable	6(11)	598,875	2	2,234,917	9
2540	Long-term loans	6(10), 8	1,136,500	3	370,000	2
2570	Deferred tax liabilities	4, 6(21)	2,407,722	7	148,741	1
2550	Long-term provision	6(13)	448,884	1	—	—
2670	Other non-current liabilities	7	2,740	—	4,537	—
25XX	Total non-current liabilities		4,594,721	13	2,804,353	12
2XXX	Total liabilities		7,627,616	22	6,848,839	28
31XX	Equity	6(14)				
3110	Share capital		7,612,257	22	7,249,768	29
3200	Capital surplus		5,036,294	15	5,535,957	22
3300	Retained earnings					
3310	Legal capital reserve		—	—	1,267,810	5
3320	Special capital reserve		5,002,321	15	5,560,363	22
3350	Unappropriated earnings		9,334,785	28	(1,368,634)	(5)
3400	Other equity					
3410	Exchange differences arising on translation of foreign operations		(14,336)	—	(739)	—
3420	Unrealized gain (loss) on financial assets at fair value through other comprehensive income		108,099	—	19,603	—
3500	Treasury shares		(592,731)	(2)	(209,651)	(1)
3XXX	Total equity		26,486,689	78	18,054,477	72
1XXX	Total liabilities and equity		$ 34,114,305	100	$ 24,903,316	100

(The accompanying notes are an integral part of the parent company only financial statements.)

Center Laboratories, Inc.

Parent Company Only Statements of Comprehensive Income

For the years ended December 31, 2025 and 2024

In Thousands of New Taiwan Dollars

(Except Earnings Per Share)

Account Code	Items	Notes	2025 Amount	2025 %	2024 Amount	2024 %
4000	Net revenue	4, 6(17)	$ 941,103	100	$ 971,710	100
5000	Cost of revenue	6(5)	476,278	51	462,403	48
5900	Gross profit		464,825	49	509,307	52
6000	Operating expenses	6(18), 7				
6100	Selling and marketing expenses		175,317	19	177,055	18
6200	General and administrative expenses		142,111	15	118,618	12
6300	Research and development expenses		40,492	4	28,801	3
6450	Expected credit impairment (gains) losses		(452)	—	—	—
	Total operating expenses		357,468	38	324,474	33
6500	Other income and (expenses), net	6(13)	(448,884)	(47)	—	—
6900	(Loss) income from operations		(341,527)	(36)	184,833	19
7000	Non-operating income and expenses					
7050	Finance costs	6(19), 7	(195,740)	(21)	(217,927)	(22)
7100	Interest income	7	28,918	3	91,692	10
7110	Rent income	7	29,965	3	40,434	4
7130	Dividend income		85,693	9	87,915	9
7190	Other income	6(19), 7	46,423	5	23,750	2
7225	Gain on disposals of investments		464,448	49	52,416	5
7230	(Loss) gain on foreign exchange		(55,586)	(6)	76,061	8
7235	Gain (loss) on financial assets/liabilities at fair value through profit or loss		16,539	2	(771,502)	(79)
7590	Other gains and losses		(172)	—	—	—
7070	Shares of profit or loss of subsidiaries, associates and joint ventures accounted for using the equity method		11,469,308	1,219	(726,143)	(75)
	Total non-operating income and expenses		11,889,796	1,263	(1,343,304)	(138)
7900	Income (loss) before income tax		11,548,269	1,227	(1,158,471)	(119)
7950	Income tax (expense) benefit	4, 6(21)	(2,225,444)	(236)	54,788	6
8200	Net income (loss)		9,322,825	991	(1,103,683)	(113)

(To be continued)

(Continued)

			2025		2024	
			Amount	%	Amount	%
8300	Other comprehensive income					
8310	Items that will not be reclassified subsequently to profit or loss	6(20)				
8311	Remeasurement of defined benefit obligation		3,179	−	3,782	−
8330	Shares of other comprehensive income or loss of subsidiaries, associates and joint ventures accounted for using the equity method		88,560	10	(54,922)	(6)
8349	Income tax (expense) relating to items that will not be reclassified to profit or loss	6(21)	(636)	−	(756)	−
8310	Total components of other comprehensive income that will not be reclassified to profit or loss		91,103	10	(51,896)	(6)
8360	Items that may be reclassified subsequently to profit or loss	6(20)				
8361	Exchange differences arising on translation of foreign operations		(9,992)	(1)	55,290	6
8380	Shares of other comprehensive income or loss of subsidiaries, associates and joint ventures accounted for using the equity method		(5,936)	(1)	5,684	−
8399	Income tax benefit (expense) relating to items that may be reclassified to profit or loss	6(21)	2,331	−	(11,317)	(1)
8360	Total components of other comprehensive income that may be reclassified to profit or loss		(13,597)	(2)	49,657	5
8500	Total comprehensive income		$ 9,400,331	999	$ (1,105,922)	(114)
	Earnings per share					
9750	Basic earnings (losses) per share	6(22)	$ 12.33		$ (1.48)	
9850	Diluted earnings (losses) per share	6(22)	$ 11.44		$ (1.48)	

(The accompanying notes are an integral part of the parent company only financial statements.)

Center Laboratories, Inc.

Parent Company Only Statements of Changes in Equity

For the years ended December 31, 2025 and 2024

In Thousands of New Taiwan Dollars

Items	Share capital	Capital surplus						Retained earnings			Other equity			Treasury shares	Total equity
		Issued at premium	Difference between consideration and carrying amount of subsidiaries acquired or disposed	Changes in net equity of associates and joint ventures accounted for using the equity method	Stock options	Treasury shares	Others	Legal capital reserve	Special capital reserve	Unappropriated earnings (Accumulated deficit to be offset)	Exchange differences arising on translation of foreign operations	Unrealized gain (loss) on financial assets at fair value through other comprehensive income	Total		
Balance as of January 1, 2024	$ 6,914,211	$ 4,866,544	$ 449,327	$ 1,046,926	$ 800,338	$ 76,827	$ 1,540	$ 1,267,810	$ 5,560,363	$ (1,004,735)	$ (50,396)	$ 74,820	$ 24,424	$ (246,721)	$ 19,756,854
Issuance of new shares (share exchange)	248,430	922,916	(449,327)	–	–	–	–	–	–	(262,401)	–	–	–	–	459,618
Deficiency compensation from capital surplus	–	(1,004,735)	–	–	–	–	–	–	–	1,004,735	–	–	–	–	–
Cash dividends from capital surplus	–	(1,037,159)	–	–	–	–	–	–	–	–	–	–	–	–	(1,037,159)
Conversion of convertible bonds to issuance of new shares	87,127	306,578	–	–	(75,268)	–	–	–	–	–	–	–	–	–	318,437
Other changes in capital surplus															
Adjustments to share of changes in equities of subsidiaries, associates and joint ventures	–	–	–	(381,050)	–	–	–	–	–	(5,871)	–	–	–	–	(386,921)
Recovery of unclaimed dividends from shareholders	–	–	–	–	–	–	69	–	–	–	–	–	–	–	69
Disposal of the parent company's share by subsidiaries recognized as treasury share transactions	–	–	–	–	–	5,115	–	–	–	–	–	–	–	37,070	42,185
Adjustment of capital surplus due to dividends distributed to subsidiary companies	–	–	–	–	–	6,513	–	–	–	–	–	–	–	–	6,513
Net income (loss) in 2024	–	–	–	–	–	–	–	–	–	(1,103,683)	–	–	–	–	(1,103,683)
Other comprehensive income in 2024	–	–	–	–	–	–	–	–	–	3,321	49,657	(55,217)	(5,560)	–	(2,239)
Share-based compensation	–	–	–	–	803	–	–	–	–	–	–	–	–	–	803
Balance as of December 31, 2024	$ 7,249,768	$ 4,054,144	$ –	$ 665,876	$ 725,873	$ 88,455	$ 1,609	$ 1,267,810	$ 5,560,363	$ (1,368,634)	$ (739)	$ 19,603	$ 18,864	$ (209,651)	$ 18,054,477
Cash dividends from capital surplus	–	(543,732)	–	–	–	–	–	–	–	–	–	–	–	–	(543,732)
Appropriation of earnings:															
Stock dividends	362,489	–	–	–	–	–	–	–	–	(362,489)	–	–	–	–	–
Legal capital reserve used to offset accumulated deficits	–	–	–	–	–	–	–	(1,267,810)	–	1,267,810	–	–	–	–	–
Reversal of special capital reserve	–	–	–	–	–	–	–	–	(558,042)	558,042	–	–	–	–	–
Other changes in capital surplus															
Expired stock options	–	–	–	–	(190,292)	–	190,292	–	–	–	–	–	–	–	–
Adjustments to share of changes in equities of subsidiaries, associates and joint ventures	–	–	–	33,386	–	–	–	–	–	(85,376)	–	–	–	–	(51,990)
Recovery of unclaimed dividends from shareholders	–	–	21	–	–	–	47	–	–	–	–	–	–	–	68
Adjustment of capital surplus due to dividends distributed to subsidiary companies	–	–	–	–	–	3,462	–	–	–	–	–	–	–	–	3,462
Repurchase of treasury shares	–	–	–	–	–	–	–	–	–	–	–	–	–	(383,080)	(383,080)
Net income (loss) in 2025	–	–	–	–	–	–	–	–	–	9,322,825	–	–	–	–	9,322,825
Other comprehensive income in 2025	–	–	–	–	–	–	–	–	–	2,607	(13,597)	88,496	74,899	–	77,506
Share-based compensation	–	–	–	–	7,153	–	–	–	–	–	–	–	–	–	7,153
Balance as of December 31, 2025	$ 7,612,257	$ 3,510,412	$ 21	$ 699,262	$ 542,734	$ 91,917	$ 191,948	$ –	$ 5,002,321	$ 9,334,785	$ (14,336)	$ 108,099	$ 93,763	$ (592,731)	$ 26,486,689

(The accompanying notes are an integral part of the parent company only financial statements.)

Center Laboratories, Inc.

Parent Company Only Statements of Cash Flows

For the years ended December 31, 2025 and 2024

	In Thousands of New Taiwan Dollars	
	2025	**2024**
Cash flows from operating activities:		
Profit (loss) before income tax	$ 11,548,269	$ (1,158,471)
Adjustments for:		
The income or loss items which did not affect cash flows		
Depreciation expense	34,774	30,538
Amortization expense	2,189	1,644
Interest expense	195,740	217,927
Interest income	(28,918)	(91,692)
Dividend income	(85,693)	(87,915)
Expected credit impairment losses (gains)	(452)	—
Realized / unrealized foreign exchange (gain) loss	8,344	(21,702)
Share-based compensation	7,153	803
Shares of profit or loss of subsidiaries, associates and joint ventures accounted for using the equity method	(11,469,308)	726,143
Loss (gain) on disposal of property, plant and equipment	166	(73)
(Gain) on disposal of investments	(464,448)	(52,416)
Current transfer expenses of construction in process	2,724	—
(Gain) loss on financial assets/liabilities at fair value through profit or loss	(16,539)	771,502
Changes in operating assets and liabilities:		
Decrease in notes receivable	3,593	28,025
Decrease in accounts receivable	4,926	6,746
(Increase) in inventories	(45,136)	(46,217)
(Increase) decrease in other current assets	(1,353)	15,213
(Increase) in net defined benefit asset	(3,068)	(2,609)
Increase (decrease) in contract liabilities	20,406	(9,806)
(Decrease) in accounts payable	(12,074)	(4,392)
Increase (decrease) in other payables	23,303	(378)
(Decrease) increase in other current liabilities	(3,975)	2,944
Increase in long-term provision	448,884	—
Cash generated from operations	169,507	325,814
Interest received	34,034	88,589
Interest paid	(57,549)	(80,930)
Income tax paid	(143,953)	(162,223)
Net cash provided by operating activities	2,039	171,250

(To be continued)

(Continued)

	2025	2024
Cash flows from investing activities:		
Acquisition of financial assets at fair value through profit or loss	(265,881)	(863,005)
Proceeds from disposal of financial assets at fair value through profit or loss	232,529	925,382
Acquisition of investments accounted for using the equity method	(207,078)	(1,430,806)
Proceeds from capital reduction of shares of investments accounted for using the equity method	216,260	673,686
Proceeds from disposal of investments accounted for using the equity method	516,505	79,154
Acquisition of financial assets at amortized cost	339,177	419,698
Acquisition of property, plant and equipment (Including prepayment for equipment)	(127,131)	(79,920)
Proceeds from disposal of property, plant and equipment	—	150
Acquisition of intangible assets	(2,373)	(3,106)
(Increase) decrease in refundable deposits	(2,731)	839
Decrease (increase) in other financial assets	867,555	(51,081)
Dividends received from subsidiaries and associates	70,225	8,357
Other dividends received	85,693	87,915
Net cash provided by (used in) investing activities	1,722,750	(232,737)
Cash flows from financing activities:		
(Decrease) increase in bank loans	(150,000)	900,000
Proceeds from long-term loans	262,000	158,000
Decrease in guarantee deposits	(1,466)	(2,475)
Cash dividends	(543,732)	(1,037,159)
Recovery of unclaimed dividends from shareholders	47	69
Repayment of the principal portion of lease liabilities	(978)	(958)
Decrease in long-term payables to related parties	—	(95,830)
Repayment of convertible bonds at maturity	(1,988,700)	—
Repurchase of treasury shares	(383,080)	—
Net cash (used in) financing activities	(2,805,909)	(78,353)
Net (decrease) in cash and cash equivalents	(1,081,120)	(139,840)
Cash and cash equivalents, beginning of period	1,184,234	1,324,074
Cash and cash equivalents, end of period	$ 103,114	$ 1,184,234

(The accompanying notes are an integral part of the parent company only financial statements.)

VI. 2025 Consolidated Financial Statements

Independent Auditors' Report

The Board of Directors and Shareholders of Center Laboratories, Inc.

Opinion

We have audited the accompanying consolidated financial statements of Center Laboratories, Inc. and its subsidiaries (the "Group"), which comprise the consolidated balance sheets as of December 31, 2025 and 2024, and the consolidated statements of comprehensive income, changes in equity and cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of material accounting policies.

In our opinion, based on our audits and the report of another auditor (please refer to the Other Matter paragraph), the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as of December 31, 2025 and 2024, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations (IFRIC), and SIC Interpretations (SIC) endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with The Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. Based on our audits and the report of another auditor, we believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements for the year ended December 31, 2025. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matters for the Group's consolidated financial statements for the year ended December 31, 2025 are stated as follows:

Assessment of investment accounted for using the equity method

Center Laboratories, Inc. currently focuses its operations on the "Industry Investment of the Biotechnology and Healthcare", and owns many invested companies in the fields of new drug development, medical devices, and the healthcare industries.

Since the assessment of investment accounted for using the equity method with material amounts involves relatively complex calculation and takes significant audit manpower, the assessment of investment accounted for using the equity method was identified as a key audit matter.

Refer to Note 4(9) of the consolidated financial statements for accounting policies. Refer to Note 6(6) of the consolidated financial statements for the disclosure of carrying amount of investment accounted for using the equity method. The audit procedures we have performed in respect of the key audit matter stated above were as follows:

1. We issued instruction referral letters to review invested companies' audited financial statements and recalculated the investment profit and loss and account balance of the invested companies based on shareholding ratio to confirm accuracy.
2. We sent confirmation letters to verify long-term equity investment information.
3. Where any deficiency occurred to an invested company, we took action to understand the main reason for the deficiency and inquired whether there is concern for continued operations and future countermeasures.
4. We reviewed reasonableness of the management staff's explanation on the assessment document of asset impairment.
5. We ascertained whether the invested company's operation still continues; if not, whether the ceased operation was properly adjusted or disclosed.

Evaluation of financial instruments

Refer to Note 4(7) of the consolidated financial statements for the accounting policies. Refer to Note 5(6) of the consolidated financial statements for the significant accounting assumptions, judgments and major sources of estimation uncertainty. Refer to Note 6(27) of the consolidated financial statements for the details on the fair value measurement of the financial instrument, the level, valuation technique, and inputs.

As of December 31, 2025, the amount of financial assets (liabilities) at fair value through profit or loss were material to the consolidated financial statements as a whole. Furthermore, the financial instruments are measured based on Level 3 inputs whose quoted prices are unobservable and relies on managerial judgment and assumptions. As a result, financial assets at fair value through profit or loss and the measurement is determined as a key audit matter. The main audit procedures we have performed in respect of the key audit matter stated above were as follows:

1. We selected appropriate samples from the details of the purchase of financial assets at fair value through profit or loss as of 2025, and examined original vouchers, bank statements, and investment appraisal reports thereof.

2. Confirmation letters stating the account balance of financial assets at fair value through profit and loss as of December 31, 2025 were issued to verify the existence of these accounts.

3. We obtained asset valuation report from independent expert outsourced by the Group to understand the evaluation model and parameters used in the measurement of the financial instruments and recalculated the fair value of selected samples of the financial instruments.

Other Matter

For the aforesaid subsidiaries disclosed in the consolidated financial statements for the year ended December 31, 2025 and 2024, the consolidated financial statements of Glac Biotech Co., Ltd. and its subsidiaries, as well as Bioflag International Corporation and its subsidiaries were not audited by the Group's CPA. Those financial statements were audited by another auditor whose reports have been thereon furnished to us, and our opinions expressed herein, insofar as it relates to the amounts for the aforesaid subsidiaries, are based solely on the report of other auditor. Total assets of the consolidated financial statements amounted to NT$1,909,607 thousand and NT$2,024,523 thousand, constituting 5.5% and 7.9% of the consolidated total assets as of December 31, 2025 and 2024, respectively; concurrently, total operating revenues amounted to NT$575,087 thousand and NT$646,159 thousand, constituting 37.9% and 39.9% of the consolidated total operating revenues for the years ended December 31, 2025 and 2024, respectively.

Among the invested companies accounted for using the equity method disclosed in the consolidated financial statements, the financial statements of BioGend Therapeutics Co., Ltd., Lumosa Therapeutics Co., Ltd., Medeon Biodesign, Inc., ANYA BIOPHARM INC., TOT BIOPHARM International Company Limited, A2 + Healthcare Venture Fund L.P., Fangyuan Growth SPC., Cytoengine Co., Ltd. and A2 + Biotech Consulting Co., Ltd. were not audited by the Group's CPA. Those financial statements were audited by another auditor whose reports have been thereon furnished to us, and our opinions expressed herein, insofar as it relates to the amounts included in the financial statements, are based solely on the report of other auditor. These investments accounted for using the equity method amounted to NT$5,164,542 thousand and NT$5,154,863 thousand, constituting 14.9% and 20.2% of the total assets as of December 31, 2025 and 2024, respectively. The share of loss from associates accounted for using the equity method amounted to NT$80,048 thousand and NT$442,364 thousand, constituting 0.69% and (37.8%) of the income (loss) before income tax for the years ended December 31, 2025 and 2024, respectively.

We have also audited the parent company only financial statements of Center Laboratories, Inc. as of and for the years ended December 31, 2025 and 2024 on which we have issued an unmodified opinion with other matter paragraph.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations (IFRIC), and SIC Interpretations (SIC) endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the Audit Committee, are responsible for overseeing the Group's financial reporting process.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.

3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

6. Obtain sufficient and appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements for the year ended December 31, 2025 and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audits resulting in this independent auditors' report are Cheng, Chung-Hao and Chi, Chia-Yu.

Ful-Fill & Co., CPAs

Taipei, Taiwan

Republic of China

March 3, 2026

<u>Notice to Readers</u>

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such consolidated financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' report and the accompanying consolidated financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' report and consolidated financial statements shall prevail.

Center Laboratories, Inc. and Subsidiaries
Consolidated Balance Sheets
As of December 31, 2025 and 2024

In Thousands of New Taiwan Dollars

Account Code	Assets	Notes	December 31, 2025 Amount	%	December 31, 2024 Amount	%
11XX	Current assets					
1100	Cash and cash equivalents	6(1)	$ 237,562	1	$ 1,442,273	6
1110	Financial assets at fair value through profit or loss	4, 6(2)	363,830	1	257,998	1
1136	Financial assets at amortized cost	4, 6(3)	61,427	—	350,009	1
1150	Notes receivable, net		20,115	—	24,106	—
1170	Accounts receivable, net	4, 6(4)	214,171	1	178,579	1
130X	Inventories	4, 6(5)	353,478	1	309,703	1
1476	Other financial assets	8	311,388	1	1,183,483	5
1470	Other current assets	7	28,091	—	35,356	—
11XX	Total current assets		1,590,062	5	3,781,507	15
15XX	Non-current assets					
1510	Financial assets at fair value through profit or loss	4, 6(2), 8	24,416,193	71	13,048,724	51
1550	Investments accounted for using the equity method	4, 6(6), 8	5,656,711	16	5,761,850	23
1600	Property, plant and equipment	4, 6(7), 8	1,839,560	5	1,415,920	5
1755	Right-of-use assets	4, 6(8)	8,511	—	17,080	—
1760	Investment properties, net	4, 6(9), 8	329,280	1	662,247	3
1780	Intangible assets	4, 6(10)	732,593	2	780,347	3
1840	Deferred tax assets	4, 6(23)	17,606	—	32,505	—
1920	Refundable deposits		11,775	—	9,127	—
1915	Prepayments		5,504	—	13,959	—
1975	Net defined benefit asset	4, 6(14)	20,327	—	13,909	—
15XX	Total non-current assets		33,038,060	95	21,755,668	85
1XXX	Total assets		$ 34,628,122	100	$ 25,537,175	100

Account Code	Liabilities and Equity	Notes	December 31, 2025 Amount	%	December 31, 2024 Amount	%
21XX	Current liabilities					
2100	Short-term loans	6(11), 8	$ 1,050,000	3	$ 1,262,000	5
2120	Financial liabilities at fair value through profit or loss	4, 6(2)	12,794	—	—	—
2130	Contract liabilities	6(19)	169,016	1	159,246	1
2170	Accounts payable		119,321	—	134,790	—
2200	Other payables	6(12), 7	176,680	1	155,967	1
2230	Current tax liabilities		81,241	—	277,325	1
2280	Lease liabilities	4, 6(8)	8,566	—	9,214	—
2320	Long-term liabilities, current portion	6(11), 6(13)	1,871,558	5	2,595,827	10
2399	Other current liabilities	7	20,432	—	22,393	—
21XX	Total current liabilities		3,509,608	10	4,616,762	18
25XX	Non-current liabilities					
2500	Financial liabilities at fair value through profit or loss	4, 6(2)	—	—	46,158	—
2527	Contract liabilities	6(19)	—	—	4,841	—
2530	Bonds payable	4, 6(13)	598,875	2	2,234,917	9
2540	Long-term loans	6(11), 8	1,175,174	3	419,998	2
2550	Long-term provision	6(15)	448,884	1	—	—
2570	Deferred tax liabilities	4, 6(23)	2,407,980	7	148,741	—
2580	Lease liabilities	4, 6(8)	—	—	8,173	—
2670	Other non-current liabilities	7	906	—	3,102	—
25XX	Total non-current liabilities		4,631,819	13	2,865,930	11
2XXX	Total liabilities		8,141,427	23	7,482,692	29
31XX	Equity attributable to shareholders of the parent	6(16)				
3110	Share capital		7,612,257	22	7,249,768	28
3200	Capital surplus		5,036,294	15	5,535,957	22
3300	Retained earnings					
3310	Legal capital reserve		—	—	1,267,810	5
3320	Special capital reserve		5,002,321	15	5,560,363	22
3350	Accumulated deficit to be offset		9,334,785	27	(1,368,634)	(5)
3400	Other equity					
3410	Exchange differences arising on translation of foreign operations		(14,336)	—	(739)	—
3420	Unrealized gain (loss) on financial assets at fair value through other comprehensive income		108,099	—	19,603	—
3500	Treasury shares	6(16)	(592,731)	(2)	(209,651)	(1)
31XX	Total equity attributable to shareholders of the parent		26,486,689	77	18,054,477	71
36XX	Non-controlling interests	6(16)	6	—	6	—
3XXX	Total equity		26,486,695	77	18,054,483	71
1XXX	Total liabilities and equity		$ 34,628,122	100	$ 25,537,175	100

(The accompanying notes are an integral part of the consolidated financial statements.)

Center Laboratories, Inc. and Subsidiaries
Consolidated Statements of Comprehensive Income
For the years ended December 31, 2025 and 2024

In Thousands of New Taiwan Dollars
(Except Earnings Per Share)

Account Code	Items	Notes	2025 Amount	2025 %	2024 Amount	2024 %
4000	Net revenue	4, 6(19)	$ 1,516,190	100	$ 1,617,869	100
5000	Cost of revenue		894,932	59	868,916	54
5900	Gross profit		621,258	41	748,953	46
6000	Operating expenses	6(20), 7				
6100	Selling and marketing expenses		235,137	16	231,430	14
6200	General and administrative expenses		214,535	14	211,241	13
6300	Research and development expenses		84,782	6	71,959	4
6450	Expected credit impairment (gains) losses		(459)	—	263	—
	Total operating expenses		533,995	36	514,893	31
6500	Other income and (expenses), net	6(15)	(448,884)	(29)	—	—
6900	(Loss) income from operations		(361,621)	(24)	234,060	15
7000	Non-operating income and expenses					
7050	Finance costs	6(21), 7	(204,358)	(13)	(227,534)	(14)
7100	Interest income		31,660	2	87,104	5
7100	Dividend income		85,693	6	87,915	5
7190	Other income	6(21), 7	62,383	4	55,910	3
7225	Gain on disposals of investments		472,854	31	88,690	6
7230	(Loss) gain on foreign exchange		(58,153)	(4)	76,952	5
7590	Other gains and losses		(215)	—	(92)	—
7060	Shares of profit or loss of associates and joint ventures accounted for using the equity method		(198,161)	(13)	(549,022)	(34)
7635	Gain (loss) on financial assets and liabilities at fair value through profit or loss		11,738,555	774	(1,024,017)	(63)
	Total non-operating income and expenses		11,930,258	787	(1,404,094)	(87)
7900	Income (loss) before income tax		11,568,637	763	(1,170,034)	(72)
7950	Income tax (expense) benefit	4, 6(23)	(2,245,812)	(148)	66,626	4
8200	Net income (loss)		9,322,825	615	(1,103,408)	(68)

(To be continued)

(Continued)

			2025		2024	
			Amount	%	Amount	%
8300	Other comprehensive income					
8310	Items that will not be reclassified subsequently to profit or loss	6(22)				
8311	Remeasurement of defined benefit obligation		3,256	—	4,095	—
8320	Shares of other comprehensive income or loss of associates and joint ventures accounted for using the equity method		88,498	6	(55,172)	(3)
8349	Income tax (expense) relating to items that will not be reclassified to profit or loss	6(23)	(651)	—	(819)	—
8310	Total components of other comprehensive income that will not be reclassified to profit or loss		91,103	6	(51,896)	(3)
8360	Items that may be reclassified subsequently to profit or loss	6(22)				
8361	Exchange differences arising on translation of foreign operations		(10,208)	(1)	55,946	3
8370	Shares of other comprehensive income or loss of associates and joint ventures accounted for using the equity method		(5,725)	—	5,374	—
8399	Income tax benefit (expense) relating to items that may be reclassified to profit or loss	6(23)	2,336	—	(11,663)	—
8360	Total components of other comprehensive income that may be reclassified to profit or loss		(13,597)	(1)	49,657	3
8500	Total comprehensive income		$ 9,400,331	620	$ (1,105,647)	(68)
8600	Net income (loss) attributable to:					
8610	Shareholders of the parent		$ 9,322,825	615	$ (1,103,683)	(68)
8620	Non-controlling interests		$ —	—	$ 275	—
8700	Total comprehensive income attributable to:					
8710	Shareholders of the parent		$ 9,400,331	620	$ (1,105,922)	(68)
8720	Non-controlling interests		$ —	—	$ 275	—
	Earnings per share					
9750	Basic earnings (losses) per share	6(24)	$ 12.33		$ (1.48)	
9850	Diluted earnings (losses) per share	6(24)	$ 11.44		$ (1.48)	

(The accompanying notes are an integral part of the consolidated financial statements.)

Center Laboratories, Inc. and Subsidiaries
Consolidated Statements of Changes in Equity
For the years ended December 31, 2025 and 2024

In Thousands of New Taiwan Dollars

Items	Equity attributable to shareholders of the parent																
		Capital surplus						Retained earnings			Other equity						
	Share capital	Issued at premium	Difference between consideration and carrying amount of subsidiaries acquired or disposed	Changes in net equity of associates and joint ventures accounted for using the equity method	Treasury shares	Others	Stock options	Legal capital reserve	Special capital reserve	Unappropriated earnings (Accumulated deficit to be offset)	Exchange differences arising on translation of foreign operations	Unrealized gain (loss) on financial assets at fair value through other comprehensive income	Total	Treasury shares	Total equity attributable to shareholders of the parent	Non-controlling interests	Total equity
Balance as of January 1, 2024	$ 6,914,211	$ 4,866,544	$ 449,327	$ 1,046,926	$ 76,827	$ 1,540	$ 800,338	$ 1,267,810	$ 5,560,363	$ (1,004,735)	$ (50,396)	$ 74,820	$ 24,424	$ (246,721)	$ 19,756,854	$ 459,349	$ 20,216,203
Issuance of new shares (share exchange)	248,430	922,916	(449,327)	–	–	–	–	–	–	(262,401)	–	–	–	–	459,618	(459,618)	–
Deficiency compensation from capital surplus	–	(1,004,735)	–	–	–	–	–	–	–	1,004,735	–	–	–	–	–	–	–
Cash dividends from capital surplus	–	(1,037,159)	–	–	–	–	–	–	–	–	–	–	–	–	(1,037,159)	–	(1,037,159)
Conversion of convertible bonds to issuance of new shares	87,127	306,578	–	–	–	–	(75,268)	–	–	–	–	–	–	–	318,437	–	318,437
Other changes in capital surplus																	
Adjustments to share of changes in equityies of associates and joint ventures	–	–	–	(381,050)	–	–	–	–	–	(5,871)	–	–	–	–	(386,921)	–	(386,921)
Recovery of unclaimed dividends from shareholders	–	–	–	–	–	69	–	–	–	–	–	–	–	–	69	–	69
Disposal of the parent company's share by subsidiaries recognized as treasury share transactions	–	–	–	–	5,115	–	–	–	–	–	–	–	–	37,070	42,185	–	42,185
Adjustment of capital surplus due to dividends distributed to subsidiary companies	–	–	–	–	6,513	–	–	–	–	–	–	–	–	–	6,513	–	6,513
Net income (loss) in 2024	–	–	–	–	–	–	–	–	–	(1,103,683)	–	–	–	–	(1,103,683)	275	(1,103,408)
Other comprehensive income in 2024	–	–	–	–	–	–	–	–	–	3,321	49,657	(55,217)	(5,560)	–	(2,239)	–	(2,239)
Share-based compensation	–	–	–	–	–	–	803	–	–	–	–	–	–	–	803	–	803
Balance as of December 31, 2024	$ 7,249,768	$ 4,054,144	$ –	$ 665,876	$ 88,455	$ 1,609	$ 725,873	$ 1,267,810	$ 5,560,363	$ (1,368,634)	$ (739)	$ 19,603	$ 18,864	$ (209,651)	$ 18,054,477	$ 6	$ 18,054,483
Cash dividends from capital surplus	–	(543,732)	–	–	–	–	–	–	–	–	–	–	–	–	(543,732)	–	(543,732)
Appropriation of earnings:																	
Stock dividends	362,489	–	–	–	–	–	–	–	–	(362,489)	–	–	–	–	–	–	–
Legal capital reserve used to offset accumulated deficits	–	–	–	–	–	–	–	(1,267,810)	–	1,267,810	–	–	–	–	–	–	–
Reversal of special capital reserve	–	–	–	–	–	–	–	–	(558,042)	558,042	–	–	–	–	–	–	–
Other changes in capital surplus																	
Adjustments to share of changes in equityies of associates and joint ventures	–	–	–	33,386	–	–	–	–	–	(85,376)	–	–	–	–	(51,990)	–	(51,990)
Expired stock options	–	–	–	–	–	190,292	(190,292)	–	–	–	–	–	–	–	–	–	–
Recovery of unclaimed dividends from shareholders	–	–	21	–	–	47	–	–	–	–	–	–	–	–	68	–	68
Adjustment of capital surplus due to dividends distributed to subsidiary companies	–	–	–	–	3,462	–	–	–	–	–	–	–	–	–	3,462	–	3,462
Repurchase of treasury shares	–	–	–	–	–	–	–	–	–	–	–	–	–	(383,080)	(383,080)	–	(383,080)
Net income (loss) in 2025	–	–	–	–	–	–	–	–	–	9,322,825	–	–	–	–	9,322,825	–	9,322,825
Other comprehensive income in 2025	–	–	–	–	–	–	–	–	–	2,607	(13,597)	88,496	74,899	–	77,506	–	77,506
Share-based compensation	–	–	–	–	–	–	7,153	–	–	–	–	–	–	–	7,153	–	7,153
Balance as of December 31, 2025	$ 7,612,257	$ 3,510,412	$ 21	$ 699,262	$ 91,917	$ 191,948	$ 542,734	$ –	$ 5,002,321	$ 9,334,785	$ (14,336)	$ 108,099	$ 93,763	$ (592,731)	$ 26,486,689	$ 6	$ 26,486,695

(The accompanying notes are an integral part of the consolidated financial statements.)

Center Laboratories, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
For the years ended December 31, 2025 and 2024

	In Thousands of New Taiwan Dollars	
	2025	**2024**
Cash flows from operating activities:		
Profit (loss) before income tax	$ 11,568,637	$ (1,170,034)
Adjustments for:		
The income or loss items which did not affect cash flows		
Depreciation expense	122,837	111,259
Amortization expense	50,467	49,812
Realized / unrealized foreign exchange loss (gain)	7,622	(20,980)
(Gain) loss on financial assets and liabilities at fair value through profit or loss	(11,738,555)	1,024,017
Expected credit impairment (gains) losses	(459)	263
Share-based compensation	7,153	803
Interest expense	204,358	227,534
Interest income	(31,660)	(87,104)
Dividend income	(85,693)	(87,915)
Shares of profit or loss of associates and joint ventures accounted for using the equity method	198,161	549,022
Loss (gain) on disposal of property, plant and equipment	167	(24)
(Gain) on disposal of investments	(472,854)	(88,690)
Current transfer expenses of construction in process	2,724	—
Changes in operating assets and liabilities:		
Decrease in notes receivable	4,313	29,901
(Increase) decrease in accounts receivable	(35,455)	11,758
(Increase) in inventories	(43,775)	(40,475)
Decrease in other current assets	4,472	25,438
(Increase) in net defined benefit asset/liability	(3,162)	(2,693)
Increase in contract liabilities	4,929	50,421
(Decrease) in accounts payable	(15,469)	(9,852)
Increase in other payables	27,118	2,411
(Decrease) in other payables to related parties	—	(629)
(Decrease) increase in other current liabilities	(1,961)	347
Increase in long-term provision	448,884	—
Cash generated from operations	222,799	574,590
Interest received	36,605	91,355
Interest paid	(66,167)	(84,774)
Income tax paid	(166,073)	(186,436)
Net cash provided by operating activities	27,164	394,735

(To be continued)

(Continued)

	2025	2024
Cash flows from operating activities:		
Acquisition of financial assets at fair value through profit or loss	(356,329)	(1,556,134)
Proceeds from disposal of financial assets at fair value through profit or loss	580,967	1,278,292
Decrease in financial assets at amortized cost	280,960	416,488
Acquisition of investments accounted for using the equity method	(197,886)	(859,839)
Proceeds from disposal of investments accounted for using the equity method	526,683	120,340
Acquisition of property, plant and equipment (Including prepayment for equipment)	(205,501)	(174,171)
Proceeds from disposal of property, plant and equipment	—	150
Acquisition of intangible assets	(2,713)	(4,320)
(Increase) decrease in refundable deposits	(2,648)	1,384
Decrease (increase) in other financial assets	872,095	(55,625)
Dividends received	157,264	96,900
Net cash provided by (used in) investing activities	1,652,892	(736,535)
Cash flows from financing activities:		
Cash dividends	(540,270)	(1,030,646)
(Decrease) increase in short-term loans	(212,000)	932,000
Proceeds from long-term loans	250,901	147,139
Decrease in guarantee deposits	(2,196)	(2,474)
Repayment of the principal portion of lease liabilities	(9,529)	(9,182)
Recovery of unclaimed dividends from shareholders	68	69
Proceeds from disposal of treasury stock	—	42,185
Repayment of convertible bonds at maturity	(1,988,700)	—
Repurchase of treasury shares	(383,080)	—
Net cash (used in) provided by financing activities	(2,884,806)	79,091
Effect of exchange rate changes on cash and cash equivalents	39	390
Net (decrease) in cash and cash equivalents	(1,204,711)	(262,319)
Cash and cash equivalents, beginning of period	1,442,273	1,704,592
Cash and cash equivalents, end of period	$ 237,562	$ 1,442,273

(The accompanying notes are an integral part of the consolidated financial statements.)

VII. 2025 Earnings Distribution Table

Center Laboratories, Inc.
Earnings Distribution Table
2025

Unit: NT$

Item	Amount
Unappropriated earnings at beginning of period	**94,729,286**
Add: Net income after tax for 2025	9,322,825,089
Less: Share of changes in equity of subsidiaries, associates, and joint ventures accounted for using the equity method	(85,376,116)
Add: Share of other comprehensive income of subsidiaries, associates, and joint ventures accounted for using the equity method	64,063
Add: Remeasurements of defined benefit plans	2,542,854
Less: Appropriation to legal reserve (10%)	(924,005,589)
Less: Appropriation to special reserve (per FSC Letter No. 1090150022)	(642,747)
Less: Appropriation to special reserve	(5,025,262,261)
Distributable earnings for the period	**3,384,874,579**
Earnings distribution:	
Shareholders' dividends – cash dividends (NT$ 1.75 per share)	(1,326,853,719)
Shareholders' dividends – stock dividends (NT$ 0.5 per share)	(379,101,070)
Unappropriated earnings at end of period	**1,678,919,790**

Chairperson: Wang, Su-Chi Managerial Officer: Hsu, Jui-Pao Accountng Officer: Mao, An-Ni

VIII. Comparison Table of Amendments to the Articles of Incorporation

Center Laboratories, Inc.

Comparison Table of Amendments to the Articles of Incorporation

Article	Original Provision	Amended Provision	Description
Article 25-2	To strengthen the Company's financial structure and safeguard investors' interests, the Company adopts a balanced dividend policy. The earnings distribution shall not be less than 50% of the distributable earnings for the year, and cash dividends shall account for no less than 10% of the total dividends distributed for the year. If the total dividend distributed for the year is less than NT$3 per share, it may be distributed entirely in the form of stock dividends.	To strengthen the Company's financial structure and safeguard investors' interests, the Company adopts a balanced dividend policy. The earnings distribution shall not be less than 10% of the distributable earnings for the year, and cash dividends shall account for no less than 10% of the total dividends distributed for the year. If the total dividend distributed for the year is less than NT$3 per share, it may be distributed entirely in the form of stock dividends.	Revised to meet operational needs.
Article 28	These Articles of Incorporation were established on October 1, 1959. ……………………………………… The 30th amendment was made on June 26, 2018. The 31st amendment was made on June 24, 2019. The 32nd amendment was made on July 1, 2021. The 33rd amendment was made on May 20, 2022. The 34th amendment was made on June 20, 2023. The 35th amendment was made on June 26, 2025.	These Articles of Incorporation were established on October 1, 1959. ……………………………………… The 30th amendment was made on June 26, 2018. The 31st amendment was made on June 24, 2019. The 32nd amendment was made on July 1, 2021. The 33rd amendment was made on May 20, 2022. The 34th amendment was made on June 20, 2023. The 35th amendment was made on June 26, 2025. The 36th amendment was made on June 12, 2026.	Revision date added.

Chaper 4 Appendices

I. Articles of Incorporation (Before Amendment)

Center Laboratories, Inc. Articles of Incorporation

Chapter I General Provisions

Article 1: The Company is organized in accordance with the Company Act and is named “晟德大藥廠股份有限公司” in Chinese and “Center Laboratories, Inc.” in English.

Article 2: The scope of business of the Company is as follows:

I. C802041 Manufacture of Drugs and Medicines
F108021 Wholesale of Western Pharmaceutical
F208021 Retail Sale of Western Pharmaceutical
F108011 Wholesale of Traditional Chinese Medicine
F208011 Retail Sale of Traditional Chinese Medicine

II. C199990 Manufacture of Other Food Products Not Elsewhere Classified (Health supplements and nutritional supplements)
C110010 Beverage Manufacturing
F203010 Retail Sale of Food, Grocery and Beverage
F102040 Wholesale of Nonalcoholic Beverages
F102170 Wholesale of Foods and Groceries

III. F108031 Wholesale of Medical Devices

IV. F208031 Retail Sale of Medical Apparatus

V. H201010 Investment

VI. ZZ99999 All business activities that are not prohibited or restricted by law, except those that are subject to special approval

Article 3: The Company may provide endorsements and guarantees to external parties.

Article 4: The total amount of the Company’s reinvestments may exceed 40% of its paid-in capital.

Article 5: The Company shall have its headquarters in Taipei City. When necessary, the Company may, upon resolution of the Board of Directors, establish branch offices within or outside the Republic of China.

Article 6: The method of public announcement of the Company shall be handled in accordance with Article 28 of the Company Act.

Chapter II Shares

Article 7: The total capital of the Company is set at NT$10,000,000,000, divided into 1,000,000,000 shares, with a par value of NT$10 per share. Of such shares, 50,000,000 shares are reserved for employee stock options, and the Board of Directors is authorized to issue the shares in installments.

Article 7-1: Where the Company issues employee stock options, issues new restricted shares for employees, transfers treasury shares to employees, or reserves a portion of newly issued shares for employee subscription in accordance with applicable laws, the recipients of such shares or rights may include employees of controlling or subordinate companies who meet certain criteria, which shall be determined by the Board of Directors.

Article 8: All share certificates of the Company shall be registered shares, affixed with the signatures or seals of directors representing the Company, and issued upon certification by the competent authority or an institution authorized for registration and issuance.

The Company may elect not to print share certificates for the shares issued, provided that such shares are registered with a centralized securities depository institution.

Article 9: All matters relating to the Company's shares, including transfer, registration of transfer, succession, gift, creation of pledge, loss or destruction, and other shareholder services, shall be handled in accordance with the "Regulations Governing the Administration of Shareholder Services of Public Companies" and relevant laws and regulations.

Article 10: Registration of transfer of shares shall be suspended during the period from sixty days prior to the date of a regular shareholders' meeting, thirty days prior to the date of a special shareholders' meeting, or five days prior to the record date determined by the Company for the distribution of dividends or other benefits.

Chapter III Shareholders' Meeting

Article 11: Shareholders' meetings shall be classified as regular meetings and special meetings. A regular shareholders' meeting shall be convened once annually by the Board of Directors within six months after the close of each fiscal year in accordance with applicable laws and regulations. A special shareholders' meeting shall be convened when necessary in accordance with applicable laws and regulations.

Article 11-1: The Company's shareholders' meetings may be held by means of a video conference or other methods as announced by the central competent authority. The conditions, procedures, and other compliance requirements for holding shareholders' meetings by video conference shall be governed by the regulations prescribed by the competent authority.

Article 12: Unless otherwise provided by applicable laws and regulations, each share shall have one voting right.

Article 13: A shareholder who is unable to attend a shareholders' meeting may appoint a proxy to attend on their behalf by executing a proxy form issued by the Company. The handling of such proxy shall be in accordance with Article 177 of the Company Act and the "Regulations Governing the Use of Proxies for Attendance at Shareholder Meetings of Public Companies."

Article 14: Unless otherwise provided by the Company Act, resolutions at a shareholders' meeting shall be adopted by a majority vote of the shareholders present who represent more than one-half of the total issued shares.

Article 14-1: The Company may, upon approval by a shareholders' meeting attended by shareholders representing more than one-half of the total issued shares and with the consent of at least two-thirds of the voting rights of the shareholders present, transfer treasury shares to employees at a price below the average purchase price, or issue employee stock options at a subscription price lower than the closing price on the date of issuance.

Article 15: Resolutions of a shareholders' meeting shall be recorded in the minutes, which shall be signed or sealed by the chairperson and distributed to all shareholders within twenty days after the meeting.

The distribution of the minutes as referred to in the preceding paragraph may be effected by public announcement.

Chapter IV Directors

Article 16: The Company shall have seven to eleven directors, who shall serve a term of three years. The candidate nomination system shall be adopted, and directors shall be elected by the shareholders' meeting from among the list of nominees. Directors may be re-elected upon expiration of their terms.

Among the foregoing number of directors, the number of independent directors shall be no fewer than three and shall not be less than one-fifth of the total number of directors. The professional qualifications, shareholding, restrictions on concurrent positions, nomination and election procedures, and other matters relating to independent directors shall be governed by the relevant regulations of the competent authority.

Article 16-1: The remuneration of directors shall be determined by the Board of Directors, taking into account the extent of their participation in the Company's operations, their contributions, and prevailing industry standards.

Article 16-2: The Company shall establish an Audit Committee in accordance with the Securities and Exchange Act. The Audit Committee shall be composed of all independent directors, and shall consist of no fewer than three members, one of whom shall serve as the convener. At least one member shall possess accounting or financial expertise. The Audit Committee and its members shall perform the duties of supervisors in accordance with the Company Act, the Securities and Exchange Act, and other applicable laws and regulations.

Article 17: Where the term of office of directors expires and re-election has not been completed, the term of office of such directors may be extended until the newly elected directors assume office. The aggregate shareholding of all directors in the Company's registered shares shall comply with the standards prescribed under the "Rules and Review Procedures for Director and Supervisor Share Ownership Ratios at Public Companies" promulgated by the competent authority.

Article 18: If the number of director vacancies reaches one-third of the total number of directors, the Board of Directors shall convene a special shareholders' meeting within sixty days to elect replacements, whose term of office shall be limited to the remaining term of the original directors.

If an independent director is dismissed for any reason, resulting in the number of independent directors falling below the number required by these Articles, a by-election shall be held at the next shareholders' meeting. If all independent directors are dismissed, the Company shall convene a special shareholders' meeting within sixty days from the date of occurrence to elect replacements.

Article 18-1: The Company may purchase liability insurance for its directors.

Article 19: The Board of Directors shall be composed of the directors. A chairman shall be elected from among the directors by a majority vote of the directors present at a meeting attended by at least two-thirds of all directors. A vice chairman may be elected in the same manner. The chairman shall represent the Company externally.

Article 19-1: A meeting of the Board of Directors shall specify the reasons for convening and shall be notified to each director at least seven days in advance; provided, however, that in case of emergency, a meeting may be convened at any time.

The notice referred to in the preceding paragraph may be given in writing, by facsimile, or by electronic mail.

Article 20: Where the chairman is on leave or unable to exercise their powers for any reason, a proxy shall be appointed in accordance with Article 208 of the Company Act.

Article 21: Where a director appoints a proxy to attend a Board meeting, such proxy shall be handled in accordance with Article 205 of the Company Act.

Article 22: (Deleted)

Chapter V Managerial Officers

Article 23: The Company may appoint one or more managerial officers. The appointment, dismissal, and remuneration of such officers shall be handled in accordance with Article 29 of the Company Act.

Chapter VI Accounting

Article 24: At the end of each fiscal year, the Board of Directors shall prepare the following:

I. Business report.

II. Financial statements.

III. Proposal for distribution of earnings or offset of losses.

The foregoing documents shall be submitted to the regular shareholders' meeting for approval in accordance with applicable laws and regulations.

Article 25: If the Company has profits for the year, it shall allocate 0.1% to 10% thereof as employee compensation and not more than 2% as directors' remuneration. However, where the Company has accumulated losses, an amount shall first be reserved to offset such losses, and the remaining amount shall then be allocated in accordance with the aforementioned ratios.

Of the employee compensation referred to in the preceding paragraph, no less than 10% shall be allocated to non-managerial employees.

Of the employee compensation referred to above, recipients of compensation in the form of shares or cash may include employees of controlled or subordinate companies who meet certain conditions, with such conditions to be determined by the Board of Directors.

Article 25-1: If the Company's annual final accounts show a surplus, it shall first pay applicable taxes and offset prior years' losses, and then set aside 10% of the remaining amount as legal reserve; provided, however, that this requirement shall not apply once the legal reserve has reached the Company's paid-in capital. After setting aside or reversing special reserves as required by law or as deemed necessary, any remaining earnings, together with the beginning unappropriated earnings, shall be proposed by the Board of Directors for distribution and submitted to the shareholders' meeting for resolution.

Article 25-2: To strengthen the Company's financial structure and safeguard investors' interests, the Company adopts a balanced dividend policy. The earnings distribution shall not be less than 50% of the distributable earnings for the year, and cash dividends shall account for no less than 10% of the total dividends distributed for the year. If the total dividend distributed for the year is less than NT$3 per share, it may be distributed entirely in the form of stock dividends.

Chapter VII Supplementary Provisions

Article 26: The organizational regulations and operational procedures of the Company shall be separately prescribed by the Board of Directors.

Article 27: Any matters not provided for in these Articles of Incorporation shall be governed by the Company Act.

Article 28: These Articles of Incorporation were established on October 1, 1959.
The 1st amendment was made on August 1, 1963.
The 2nd amendment was made on November 1, 1970.
The 3rd amendment was made on May 26, 1975.
The 4th amendment was made on July 8, 1975.
The 5th amendment was made on July 19, 1981.
The 6th amendment was made on May 1, 1982.
The 7th amendment was made on October 11, 1984.
The 8th amendment was made on November 15, 1985.
The 9th amendment was made on April 27, 1990.
The 10th amendment was made on March 25, 1996.
The 11th amendment was made on August 26, 1998.
The 12th amendment was made on June 26, 1999.
The 13th amendment was made on May 22, 2000.
The 14th amendment was made on June 23, 2000.
The 15th amendment was made on March 15, 2002.
The 16th amendment was made on November 22, 2002.
The 17th amendment was made on March 13, 2003.
The 18th amendment was made on June 20, 2003.
The 19th amendment was made on May 11, 2004.
The 20th amendment was made on June 24, 2005.
The 21st amendment was made on June 15, 2006.

The 22nd amendment was made on June 13, 2007.
The 23rd amendment was made on June 16, 2009.
The 24th amendment was made on June 14, 2010.
The 25th amendment was made on June 19, 2012.
The 26th amendment was made on June 10, 2013.
The 27th amendment was made on June 27, 2014.
The 28th amendment was made on February 26, 2016.
The 29th amendment was made on June 20, 2016.
The 30th amendment was made on June 26, 2018.
The 31st amendment was made on June 24, 2019.
The 32nd amendment was made on July 1, 2021.
The 33rd amendment was made on May 20, 2022.
The 34th amendment was made on June 20, 2023.
The 35th amendment was made on June 26, 2025.

II. Rules of Procedure for Shareholders' Meetings

Center Laboratories, Inc.
Rules of Procedure for Shareholders' Meetings

Article 1: These Rules are established in accordance with Article 5 of the Corporate Governance Best Practice Principles for TWSE/TPEx Listed Companies in order to establish a sound governance system for the Company's shareholders' meetings, strengthen supervisory functions, and enhance management functions, and shall be complied with accordingly.

Article 2: Unless otherwise provided by applicable laws and regulations or the Articles of Incorporation, the proceedings of the Company's shareholders' meetings shall be conducted in accordance with these Rules.

Article 3: Unless otherwise provided by applicable laws and regulations, shareholders' meetings shall be convened by the Board of Directors.

The Company shall, at least thirty days prior to a regular shareholders' meeting or fifteen days prior to a special shareholders' meeting, prepare electronic files of the meeting notice, proxy forms, and explanatory materials relating to proposals for approval, discussion, election or dismissal of directors, and other agenda items, and upload them to the Market Observation Post System (MOPS).

The Company shall also, at least twenty-one days prior to a regular shareholders' meeting or fifteen days prior to a special shareholders' meeting, upload the shareholders' meeting handbook and supplementary materials to MOPS. At least fifteen days prior to the meeting, the Company shall prepare the shareholders' meeting handbook and supplementary materials for shareholders' inspection at any time, and shall also make them available at the Company and its designated shareholder services agent, and distribute them at the meeting venue.

The notice and public announcement shall specify the reasons for convening the meeting. With the consent of the recipient, such notice may be given in electronic form.

Matters including the election or dismissal of directors, amendments to the Articles of Incorporation, capital reduction, application for cessation of public offering, approval of directors' non-competition, capitalization of earnings, capitalization of capital reserves, dissolution, merger, demerger, or any matters specified in Article 185, paragraph 1 of the Company Act shall be set out in the notice of meeting, together with their principal contents, and shall not be raised by ad hoc motions. The principal contents may be posted on a website designated by the competent authority or the Company, provided that the website address shall be stated in the notice.

Where the notice of meeting specifies a full re-election of directors and states the date of assumption of office, the date of assumption shall not be altered at the same meeting by extemporary motion or otherwise after the re-election has been completed.

A shareholder holding one percent or more of the total issued shares may submit one proposal for a regular shareholders' meeting; proposals exceeding one item shall not be included in the agenda. However, proposals submitted by shareholders to urge the Company to promote public interest or fulfill social responsibility may still be included at the discretion of the Board of Directors. If any shareholder proposal falls under the circumstances specified in Article 172-1, paragraph 4 of the Company Act, the Board of Directors may resolve not to include it in the agenda.

The Company shall, prior to the book closure date for the regular shareholders' meeting, publicly announce the acceptance of shareholder proposals, including the method (written or electronic), place, and period for submission, which shall not be less than ten days.

Each shareholder proposal shall be limited to 300 words. Proposals exceeding this limit shall not be included in the agenda. The proposing shareholder shall attend the meeting in person or by proxy and participate in the discussion of the proposal.

The Company shall notify proposing shareholders of the handling results prior to the issuance of the meeting notice and include proposals that comply with these Rules in the notice. For proposals not included in the agenda, the Board of Directors shall explain the reasons at the shareholders' meeting.

Article 4: A shareholder may appoint a proxy to attend a shareholders' meeting by issuing a proxy form provided by the Company, specifying the scope of authorization.

Each shareholder shall issue only one proxy and appoint only one proxy agent, and such proxy form shall be delivered to the Company no later than five days prior to the meeting. Where duplicate proxy forms are received, the one received first shall prevail. The foregoing shall not apply where a prior proxy has been revoked.

After a proxy form has been delivered to the Company, if a shareholder intends to attend the meeting in person or to exercise voting rights in writing or by electronic means, a written notice of revocation shall be submitted to the Company no later than two days prior to the meeting; otherwise, the voting rights exercised by the proxy shall prevail.

Article 5: The venue of the shareholders' meeting shall be at the location of the Company or a place convenient for shareholders' attendance and suitable for holding the meeting. The meeting shall not commence earlier than 9:00 a.m. or later than 3:00 p.m. The venue and time shall give due consideration to the opinions of independent directors.

Article 6: The Company shall specify in the meeting notice the time for shareholder registration, the place of registration, and other relevant matters.

The registration time shall commence at least thirty minutes prior to the meeting. The registration area shall be clearly marked and staffed with adequate and competent personnel.

Shareholders or their proxies (hereinafter referred to as "shareholders") shall attend the meeting upon presentation of attendance certificates, sign-in cards, or other proof of attendance. The Company shall not arbitrarily require additional supporting documents beyond those necessary for attendance. Proxy solicitors shall also carry identification documents for verification.

The Company shall maintain a sign-in book for shareholders' signatures or accept attendance cards in lieu thereof.

The Company shall provide attending shareholders with the meeting handbook, annual report, attendance certificates, speaking slips, voting ballots, and other meeting materials. Where directors are to be elected, election ballots shall also be provided.

Where a government entity or juridical person is a shareholder, more than one representative may attend the meeting. However, where a juridical person is represented by proxy, only one representative may attend.

Article 7: Where a shareholders' meeting is convened by the Board of Directors, the chairperson shall be the Chairman. If the Chairman is on leave or unable to exercise their powers for any reason, the Vice Chairman shall act as proxy. If there is no Vice Chairman, or if the Vice Chairman is also on leave or unable to exercise their powers, the Chairman shall designate one managing director to act as proxy; if no managing directors have been appointed, a director shall be designated. Where no proxy is designated, one managing director or director shall be elected from among themselves to act as proxy.

Where the chairperson referred to in the preceding paragraph is a managing director or director acting as proxy, such person shall have served for more than six months and be familiar with the Company's financial and operational conditions. The same shall apply where the chairperson is a representative of a corporate director.

For shareholders' meetings convened by the Board of Directors, the Chairman should preside in person, and a majority of the directors, as well as at least one representative from each functional committee, should attend. Attendance shall be recorded in the minutes.

Where a shareholders' meeting is convened by a person with convening authority other than the Board of Directors, the chairperson shall be such convening person. Where there are two or more such persons, one shall be elected from among them to serve as chairperson.

The Company may appoint its retained attorneys, certified public accountants, or relevant personnel to attend the shareholders' meeting.

Article 8: The Company shall make uninterrupted audio and video recordings of the entire process of shareholder registration, the proceedings of the meeting, and the vote counting process, starting from the time shareholders begin registering.

The recordings referred to in the preceding paragraph shall be retained for at least one year. However, where a shareholder files a lawsuit pursuant to Article 189 of the Company Act, the recordings shall be retained until the conclusion of such litigation.

Article 9: Attendance at a shareholders' meeting shall be calculated based on shares. The number of shares represented by shareholders present shall be calculated based on the sign-in book or attendance cards submitted, together with the number of shares for which voting rights are exercised in writing or by electronic means.

When the scheduled meeting time arrives, the chairperson shall call the meeting to order. However, if shareholders representing more than one-half of the total issued shares are not present, the chairperson may postpone the meeting, provided that such postponement shall be limited to two times and shall not exceed a total of one hour. If, after two postponements, the number of shares represented by attending shareholders is still less than one-third of the total issued shares, the chairperson shall declare the meeting adjourned.

If, after two postponements, shareholders representing at least one-third of the total issued shares are present, a tentative resolution may be adopted pursuant to Article 175, paragraph 1 of the Company Act, and notice of such tentative resolution shall be given to all shareholders, and another shareholders' meeting shall be convened within one month.

Before the meeting is adjourned, if the number of shares represented by attending shareholders reaches more than one-half of the total issued shares, the chairperson may resubmit the tentative resolution for a vote in accordance with Article 174 of the Company Act.

Article 10: Where a shareholders' meeting is convened by the Board of Directors, the agenda shall be set by the Board of Directors. All proposals (including extemporary motions and amendments to original proposals) shall be voted on item by item. The meeting shall proceed in accordance with the scheduled agenda, which shall not be changed without a resolution of the shareholders' meeting.

Where a shareholders' meeting is convened by a person with convening authority other than the Board of Directors, the provisions of the preceding paragraph shall apply mutatis mutandis.

Before the scheduled agenda (including extemporary motions) has been completed, the chairperson shall not adjourn the meeting without a resolution. If the chairperson adjourns the meeting in violation of the Rules, other members of the Board of Directors shall promptly assist the attending shareholders in electing a new chairperson, by a majority vote of the voting rights represented, to continue the meeting.

The chairperson shall allow sufficient opportunity for explanation and discussion of each proposal and any amendments or ad hoc motions proposed by shareholders. When the chairperson considers that a proposal has been sufficiently discussed and is ready for voting, the chairperson may announce the closure of discussion, submit the proposal for voting, and allocate sufficient time for voting.

Article 11: Before speaking, an attending shareholder shall complete a speaking slip specifying the subject of the speech, the shareholder account number (or attendance certificate number), and the shareholder's name. The order of speaking shall be determined by the chairperson.

A shareholder who has submitted a speaking slip but does not speak shall be deemed not to have spoken. Where the content of the speech differs from that indicated on the speaking slip, the actual speech shall prevail.

Unless otherwise permitted by the chairperson, each shareholder may speak no more than twice on the same proposal, and each speech shall not exceed five minutes. Where a shareholder's speech violates the Rules or exceeds the scope of the agenda, the chairperson may stop the speech.

While a shareholder is speaking, no other shareholder may interfere unless permitted by both the chairperson and the speaking shareholder. Any violation shall be stopped by the chairperson.

Where a corporate shareholder appoints two or more representatives, only one representative may speak on the same proposal.

After a shareholder has spoken, the chairperson may respond in person or designate relevant personnel to respond.

Article 12: Voting at a shareholders' meeting shall be calculated based on shares.

Shares held by shareholders without voting rights shall not be counted in the total number of issued shares.

Where a shareholder has a personal interest in a matter under consideration that may be detrimental to the Company's interests, such shareholder shall not participate in the voting and may not act as a proxy for another shareholder in exercising voting rights.

Shares for which voting rights may not be exercised as set forth in the preceding paragraph shall not be counted in the voting rights represented by attending shareholders.

Except for trust enterprises or shareholder services agents approved by the securities competent authority, where a person acts as proxy for two or more shareholders, the voting rights represented shall not exceed 3% of the total voting rights of the issued shares; any excess portion shall not be counted.

Article 13: Each share shall have one voting right, except where restricted or where voting rights are not granted pursuant to Article 179, paragraph 2 of the Company Act.

When the Company convenes a shareholders' meeting, voting rights shall be exercised by electronic means and may also be exercised in writing. The method of exercising voting rights shall be specified in the meeting notice. A shareholder who exercises voting rights in writing or by electronic means shall be deemed to have attended the shareholders' meeting in person; however, such shareholder shall be deemed to have abstained from voting on any extemporary motions and amendments to original proposals.

A shareholder exercising voting rights in writing or by electronic means shall deliver their expression of intent to the Company no later than two days prior to the meeting. Where duplicate expressions are received, the one received first shall prevail. This shall not apply where a prior expression has been expressly revoked.

If a shareholder who has exercised voting rights in writing or by electronic means wishes to attend the meeting in person, the prior expression of intent shall be revoked in the same manner no later than two days prior to the meeting; otherwise, the voting rights exercised shall prevail. Where a shareholder exercises voting rights in writing or by electronic means and also appoints a proxy, the voting rights exercised by the proxy shall prevail.

Unless otherwise provided by the Company Act or the Articles of Incorporation, resolutions shall be adopted by a majority vote of the voting rights represented by the attending shareholders. When voting, the chairperson or a designated person shall first announce the total number of voting rights represented by the attending shareholders, after which voting shall be conducted on each proposal. The results, including the number of votes for, against, and abstentions, shall be uploaded to MOPS on the same day.

Where there are amendments or substitute proposals to the same proposal, the chairperson shall determine the order of voting together with the original proposal. If one proposal is approved, the others shall be deemed rejected and need not be voted on again.

Vote monitoring and counting personnel shall be designated by the chairperson, provided that vote monitoring personnel shall be shareholders.

Vote counting for proposals or elections shall be conducted in a public area at the meeting venue, and the results, including the number of voting rights, shall be announced on-site and recorded.

Article 14: Where directors are to be elected at a shareholders' meeting, the election shall be conducted in accordance with the Company's relevant election rules, and the results, including the list of elected directors and the number of voting rights received by each, shall be announced on-site.

The ballots for such elections shall be sealed and signed by the vote monitoring personnel and properly kept for at least one year. However, where a shareholder files a lawsuit pursuant to Article 189 of the Company Act, the recordings shall be retained until the conclusion of such litigation.

Article 15: Resolutions of the shareholders' meeting shall be recorded in the minutes, which shall be signed or sealed by the chairperson and distributed to all shareholders within twenty days after the meeting. The preparation and distribution of the minutes may be effected by electronic means.

The distribution of the minutes referred to in the preceding paragraph may be effected by way of public announcement through MOPS.

The minutes shall accurately record the year, month, day, venue, name of the chairperson, method of resolution, summary of proceedings, and voting results (including the number of voting rights). Where directors are elected, the number of voting rights received by each candidate shall also be disclosed. The minutes shall be permanently retained during the existence of the Company.

Article 16: The number of shares solicited by proxy solicitors and the number of shares represented by proxy agents shall be compiled in a statistical table in the prescribed format and clearly disclosed at the meeting venue on the day of the shareholders' meeting.

Where any resolution of the shareholders' meeting constitutes material information under applicable laws or the rules of the Taiwan Stock Exchange or the Taipei Exchange, the Company shall upload the relevant information to MOPS within the prescribed time.

Article 17: Personnel handling meeting affairs shall wear identification badges or armbands.

The chairperson may direct attendants or security personnel to assist in maintaining order at the venue. Attendants or security personnel assisting in maintaining order shall wear armbands or identification bearing the words "Attendants."

Where sound amplification equipment is provided at the venue, shareholders shall not speak using equipment not provided by the Company; otherwise, the chairperson may stop such conduct.

Where a shareholder violates the Rules, fails to comply with the chairperson's instructions, and disrupts the proceedings, the chairperson may direct attendants or security personnel to escort such shareholder out of the venue.

Article 18: During the meeting, the chairperson may announce a recess at their discretion. In the event of force majeure, the chairperson may suspend the meeting and announce the time for resumption depending on the circumstances.

If the meeting venue becomes unavailable before the agenda (including extemporary motions) is completed, the shareholders' meeting may resolve to relocate and continue the meeting at another venue.

The shareholders' meeting may resolve to postpone or continue the meeting within five days in accordance with Article 182 of the Company Act.

Article 19: These Rules shall take effect upon approval by the shareholders' meeting. The same shall apply to any amendments hereto.

III. Shareholdings of Directors

(I) Minimum Shareholding Requirement for All Directors and Shareholdings as Recorded in the Shareholders' Register

Title	Minimum required shareholding	Shareholdings as recorded in the shareholders' register as of book closure date
Director	24,600,807	141,250,516

Note: Book closure date: April 14, 2026

(II) Details of Directors' Shareholdings

Title	Name	Shareholdings as recorded in the shareholders' register as of book closure date
Chairperson	Jason Technology Co., Ltd. Representative Wang, Su-Chi	26,712,148
Director	Tsai, Chang-Hai	0
Director	Chang, Po-Chih	1,347,762
Director	Lejean Biotech Co., Ltd. Representative: Lin, Chia-Ling	69,515,316
Director	Royal Foods Co., Ltd.	43,591,235
Director	Po Chang Investment Co., Ltd.	84,055
Independent Director	Ho, Mei-Yueh	0
Independent Director	Ho, Shih-Chun	0
Independent Director	Kuo, Li-Wei	0

Note: Book closure date: April 14, 2026

IV. The impact of the proposed stock dividend at the shareholders' meeting on the company's operating performance and earnings per share: As the Company has not prepared financial forecasts, the impact is not applicable.